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Abstract 
              (25R)-3β-Hydroxy-5α-spirostan-12-one (hecogenin) and 11α-hydroxypregn-4-ene-
3,20-dione (11α-hydroxyprogesterone) were used as starting materials for the synthesis of a 
series of 11- and 12-substituted derivatives of 5ξ-pregnanolone (3α-hydroxy-5α-pregnan-20-
one and 3α-hydroxy-5-pregnan-20-one), the principal neurosteroid acting via γ-aminobutyric 
acid (GABA). These analogues were designed to study the structural requirements of the 
corresponding GABAA receptor. Their biological activity was measured by in vitro test with 
[
3
H]-flunitrazepam as radioligand in which allopregnanolone and its active analogues 
stimulated the binding to the GABAA receptor.  Analysis of the SAR data suggests 
dependence of the flunitrazepam binding activity on the lipophobic-lipophilic balance of the 
groups at the C-ring edge, rather than on specific interactions between them and the receptor.  
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Introduction  
 
     Although steroids in general are widely understood as a class of natural products, which 
hold only little potential of a new breakthrough, neurosteroids are still studied with great 
interest (see the “Neurosteroid” copy1,2 of Pharmacol. Ther. 2007 or recent papers3-6). Unlike 
the family of other steroid hormones, neurosteroids do not bind to nuclear but to membrane 
receptors for neurotransmitters. One of the neurotransmitters - γ-aminobutyric acid (GABA) 
elicits the influx of chloride ions into neuronal cells, which changes the membrane potential 
of a given cell, which in turn prevents the transmission of subsequent neuronal signals.  
    In agreement with this action, neurosteroids such as allopregnanolone or pregnanolone (1a 
and 1b, respectively, see Figure 1), 3α,5α-tetrahydrodeoxycorticosterone (2), and some of 
their analogues, acting via the GABAA receptor, have anxiolytic, anaesthetic, anticonvulsant, 
and sedative properties.
7,8
 Many new types of such analogues were prepared in order to refine 
the knowledge of relationship between the structure of compounds and their neuronal activity. 
These analogues either involve compounds with additional substituents (eg., alphaxalone, 3), 
or have their skeleton modified by increasing
9
 or decreasing
10-12
 the flexibility of the molecule 
or even reversing its chirality.
13
 Various changes were also made to the steroid side chain.
14-17 
 
Even heteroatoms (O, N, S) were introduced into the steroid framework with varied 
success.
18-21
 
    Almost all the active analogues contained a hydroxyl group in position 3α. Its presence has 
been considered essential for the activity, even though a 3α-amino analogue, lacking the 3α-
hydroxyl (i. e., 4) retained 56% of the activity of allopregnanolone.
22
  
    In our search for new analogues of allopreganolone, we prepared a number of 5-pregnane 
derivatives designed to exert a higher solubility in water than the principal neurosteroid 1a. 
The biological activity of the new products was assessed using in vitro tests, which measured 
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the binding of labelled ligands to GABAA receptors in the absence and presence of the tested 
compounds. In our previous paper we reported structure modification of the steroidal B ring.
11
 
Some anomalies in the structure of the analogues were tolerated by the GABAA receptor, 
others not; the biological consequences of the structure modification were rationalized using 
methods of molecular modelling. A similar study of the effect of C ring substituents upon the 
activity of neurosteroid analogues is the subject of this paper, which also takes into account 
earlier results published by other authors.
23-26 
 
Results and Discussion     
 
Synthesis of 12-substituted analogues.  Hecogenin (5, see Scheme 1) was used as a readily 
available synthon with position 20 masked for subsequent transformations. The inversion of 
configuration of the 3β-hydroxy group in hecogenin (5) was first carried out at the beginning 
of the process using solvolysis of corresponding 3β mesylate 6 and tosylate 7 with potassium 
nitrite in DMF, which afforded the target 3α alcohol 8 in overall yields 26% and 40%, 
respectively. The 3α-hydroxy group formed was then protected by esterification, and 12 oxo 
group in benzoate 9 was reduced with sodium borohydride to yield 12β-alcohol 10. The 
expected 12β-configuration of this compound as well as of other products was confirmed by 
1
H NMR spectroscopy (see the Experimental Section). 
  The degradation of the spirostane system, using acetic anhydride at 190 
o
C, oxidation 
and pyrolysis, was carried out in 12β alcohol 10.27 Crude product was immediately 
hydrogenated on palladium to afford diester 11. Its hydrolysis yielded another target - 12β-
hydroxy-allopregnanolone (12). However, the overall yield from hecogenin was very low 
(6%) probably due to a low stability of the axial substituent in position 3 during the spirostane 
degradation step. Partial hydrolysis of the diester 11 in position 12 and subsequent 
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dehydration and hydrolysis produced another analogue sought - allopregn-11-enolone (13). 
Alternatively, the sequence of hecogenin transformation reaction was reversed: the spirostane 
system was first oxidised into a pregn-16-ene derivative in much better yields (71%). 
Standard hydrogenation, hydrolysis, and oxidation produced triketone 14. The desired 3α-
hydroxyl group was then introduced under conditions of the Henbest reaction, i. e., by 
reduction of the 3-oxo group with hot 2-propanol and phosphorous acid catalyzed with 
hydrogen hexachloroiridate.
28,29
 The reaction yielded another allopregnanolone derivative - 
3α,12α-dihydroxy-5α-pregnan-20-one30 (15). 
    The preparation of 12ξ-acetamino analogues started with the preparation of oxime 16. 
Contrary to the above hydride reduction of 12-ketone, the sodium borohydride reduction 
under catalysis of molybdenum trioxide proceeded in a non-stereospecific manner: both 
amines 17 and 18 were formed in almost equal yields. Both were subjected to the above four-
step degradation of the spirostane system: the equatorial amine 18 yielded 12β-acetamino-
allopregnanolone 19; no 12α-acetamino derivative, however, was isolated from the same 
treatment of amine 17.  
 For the synthesis of free 12-amino derivative of allopregnanolone, Leuckart-
Wallach’s reductive amination of 3β-acetoxy-5α-pregnane-12,20-dione31 (20) was used (see 
Scheme 2): the major product 21 was a tert.butoxycarbonyl (BOC) protected 12β-amino 
derivative 21, which was hydrolyzed and inverted at carbon 3, yielding compounds 22 and 23, 
respectively. On deprotection of the latter with trifluoroacetic acid, the 12β-amino analogue 
24 was formed. 
 
Synthesis of 11-substituted analogues. The synthesis of 5β analogues (see Scheme 3) was 
based on commercial 11α-hydroxyprogesterone (25), which was hydrogenated on palladium 
catalyst in pyridine to yield 11α-hydroxy-5β-pregnane-3,20-dione (26) besides some 5α-
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isomer 27 (5%). Partial reduction of diketone 26 with sodium borohydride in pyridine 
produced a 11α-hydroxy analogue of pregnanolone32-34 28. For subsequent reactions, the 3 
and 20 oxo groups were protected by treatment with ethylene glycol: compound 26 produced 
(after oxidation) a diketal 29, similarly, compound 28 gave (after oxidation) a mono ketal
35 
30. The latter reacted with lithium aluminum hydride and Grignard reagents to yield 3α,11β-
diols 31 to 33, respectively, or with sodium borohydride in pyridine to produce the known 5 
alphaxolone analogue
32 
34. Analogously, diketal 29 was converted into 3,20-dioxo derivatives 
35 and 36, which were reduced with sodium borohydride to other analogues, compounds 37 
and 38. 
   The above side product of hydrogenation, 11α-hydroxy-5α-pregnane-3,20-dione (27, 
scheme 4) was utilized for the preparation of 11α-hydroxy allopregnanolone (39), although 
the Henbest reaction (i.e., reduction with 2-propanol catalyzed with iridium salts) had to be 
used instead of a hydride reduction.
36
 Other allopregnanolone analogues were prepared from 
enol acetate 40: hydrogenation
37
 and hydrolysis produced 3-hydroxy-5α-pregnane-11,20-
dione (41) accompanied with a lipophilic product of hydrogenolysis.
38
 Solvolysis of the 
corresponding mesylate 42 and deprotection yielded 3α-hydroxy-5α-pregnane-11,20-dione39 
(3). Its more reactive 20-oxo group was protected by ketalization, ketal 43 was then treated 
with LAH or ethynyl magnesium bromide under the formation (after deprotection) of two 
other analogues, 11-alcohols 44 and 45.40  
    Oximation of 11-ketone 43 produced a mixture of oximino derivatives
41 
46, which was 
reduced either with sodium in boiling 2-propanol,
42
 selectively yielding equatorial 11α- amine 
47 or with NaBH4 in the presence of MoO3, selectively producing the axial 11-amine 48.  
    Another type of allopregnanolone with a polar functionality below the C-ring was obtained 
from olefin 13 (Scheme 1). Epoxidation of this compound with a peroxy acid yielded 
11α,12α-epoxide 49 only.  
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    Contrary to the above analogues with polar functional groups in the C ring, some lipophilic 
analogues were prepared and tested too (see Scheme 5). Suitable 11-deoxy analogues were 
prepared from 5ß- and 5α-diketals 29 and 50 on treatment with methyl lithium. Tertiary 
alcohols 51 and 52 were dehydrated and de-protected to yield corresponding mixtures of 11-
exomethyleno derivatives (53 and 54, respectively) and 11-methyl-Δ9(11)- derivatives (55). 
These 3-oxo compounds were reduced as above (i.e., the 5α-isomer 53 was reduced according 
to Henbest, the 5 isomer 54 was reduced with sodium borohydride) to give unsaturated 
homologues of allopregnanolone and pregnanolone, compounds 56 to 58. These were 
hydrogenated to afford 11-methyl allopregnanolone and pregnanolone derivatives 59 and 60, 
respectively. 
 
Biological Activity at the GABAA receptor and SAR analysis. 
   Previously,
11,43,44
 we have reported that an increase of [
3
H]-flunitrazepam binding 
corresponds to activation/potentiation of the GABAA receptor, as measured by the chloride 
anion influx. Both allopregnanolone and pregnanolone increase [
3
H]-flunitrazepam binding in 
a dose dependent manner with effective concentration (EC50) around 1 μM and a maximum 
effect (Emax) around 160% of the basal binding.
11
 In that work, the [
3
H]-flunitrazepam binding 
to the GABAA receptor was carried out with allopregnanolone analogues modified in the B-
ring.
11
 3α-Hydroxy-7-nor-5ξ-pregnan-20-one analogues showed activity at the GABAA 
receptor, whereas other analogues carrying electronegative substituents in the B-ring were 
inactive.   
   In the present work the effect of modifications in the neurosteroids C-ring on [
3
H]-
flunitrazepam binding has been assessed in primary cultures of intact living cortical neurons 
(see Table 1). The binding was measured in the presence of the varying concentration of these 
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compounds. A fixed concentration of allopregnanolone (60 μM, the concentration that 
produces maximal effect) was included in each assay.   
 
   In general, introduction of a double bond into the C-ring (ie. 13 and 58) or small non-polar 
substituents at C11 (ie. 56, 57, 58, 59, and 60) rendered compounds active, with similar or 
moderately higher EC50 values than those reported for the parent neurosteroids 
allopregnanolone (1a) and pregnanolone (1b) (0.88 μM and 1.18 μM, respectively11). The 
exomethyleno analogue of allopregnanolone 56, which could be considered as an isostere of 
alphaxolone, was the most active among the 5α-series. It is noteworthy that the related 
allopregnanolone  derivative containing a C-ring Δ9(11)-double bond (61) was reported to be 
similarly active in a flunitrazepam binding assay.
25
 On the other hand, the 5-analogue 57 
showed >30-fold decrease in activity relative to 1b. 
   Incorporation of an 11-OH or –NH2 group into the structure of 1a led to compounds (44 
and 48, respectively) with similar efficiency, as represented by the E100µM value (Table 1),  
but again slightly (48, 7-fold) or moderately (44, 36-fold) reduced potency relative to 
allopregnanolone. Contrarily, 11-hydroxylation of the pregnanolone produced the 5-
analogue 31 with very low activity.  
   Inversely, introduction of an 11α-OH or –NH2 substituent or an 11α,12α epoxy group into 
the structure of the 5α-steroids lead to compounds with much lower (47, 175-fold less active 
than 1a) or null activity (39, 49): the 11α amine is 175-fold less active than allopregnanolone 
(1a). In the 5ß series, the effect of an 11α-OH upon the activity is 60 times reduced (compare 
compounds 28 and 1b).  
   The presence of an 11-oxo group had a little effect on the flunitrazepam binding activity in 
the 5α-series (see alphaxolone, compound 3) but it caused a 80-fold decrease (relative to 1b) 
in the activity of its 5-analogue 34. Similar results on flunitrazepam binding had been 
reported in the literature for 11-oxo derivatives 3 and 34
26, and 11α-hydroxy derivatives 28 
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and 39
25
 whereas the anaesthetic activity of 11ξ-alcohols 31, 39, 44, and amine 47 in mice 
was found much lower than that of 11-ketone (alphaxolone 3).
23,24
 
    The different behaviour of these 5α- and 5-analogues is in agreement with the evidence 
for different binding sites for 5α- and 5-neurosteroids at the GABAA receptor,
2,11 
and implies 
different tolerance for polar C-ring substituents at each site. In this sense, the incorporation of 
a non-polar 11α-acetylenic or phenylacetylenic group in addition to the 11-OH group 
recovered the activity of the 5-compounds (compounds 37 and 38 vs 31) but left it 
unchanged for the 5α-analogue (compound 45 vs 44). It is remarkable that the 11α-
phenylethynyl-11-hydroxyl derivative 38, the most active in the 5-series, exhibits 
essentially the same activity as the parent neurosteroid 1b. Other neuroactive steroids with 
relatively large 11α-substituents (ie. minaxolone) have been reported.45 Interestingly, the 
presence of an additional 3-acetylene or phenylacetylene substituent in the 5-compounds 
led to a decrease of activity (32 and 33 vs 37 and 38). This is in contrast with the proposed 
existence of an auxiliary binding pocket in the 5-neurosteroid binding site, that could 
allocate small lipophilic as well as phenylacetylenic 3-substituents present in several 
analogues that have shown a high inhibitory activity in TBPS binding assays.
46, 47  
 
    The introduction of polar groups in the equatorial 12-position of the 5α-neurosteroid 
series decreased the activity even more than those in 12α-position and than those in position 
11. Thus, 12-hydroxy, amino or acetamido derivatives 12, 24, and 19 were less active than 
their 11-counterparts analogues 44 and 48, while the 12α-hydroxy derivative 15 was more 
active than the corresponding 12-hydroxy 12 and 11α-hydroxy 39 derivatives. 
    In summary, the structure-activity dependence of the compounds analysed in the present 
study indicates that modifications at the C11-C12 C-ring edge of 5ξ-pregnanolones, which do 
not imply large local changes of polarity, are relatively well tolerated by the GABAA 
neurosteroid receptor, while introduction of polar groups at C11 or C12 is in general more 
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detrimental for the activity. This negative effect can be compensated, in some cases,  by the 
introduction of additional lipophilic groups in the same region. There are some exceptions to 
this trend evidenced by compounds such as 48, which although having a polar 11β-amino 
substitution showed similar potency and efficiency to other more hydrophobic derivatives, 
like its isosteric 11β-methyl analogue 59. 
    Different studies recently published indicated that the steroid binding sites on the GABAA 
receptor are located on transmembrane domains of the protein.
48-50
 Accordingly it has been 
suggested that the effective steroid concentration in the lipid membrane, rather than aqueous 
concentration, as well as intracellular accumulation, contribute to the potency and longevity 
of their action.
51-54
 Chisari et al. observed a good correlation between the potentiating activity 
of the neuroactive steroids allopregnanolone (1a), (3α5α)-3,21-dihydroxypregnan-20-one (2), 
alphaxolone (3), alphadolone (the 11-oxoderivative of 2) and ZCM41 (the 11α-methyl-11-
benzyloxy derivative of 1a) and their average logP estimates determined from 11 different 
algorithms.
52
 Similarly, we have determined the logP values for the compounds analysed in 
this work, as well as their predicted water solubility, using different algorithms (Tables S2 
and S3, Supporting Information). The variance of flunitrazepam binding showed a slight 
correlation with predicted water solubility (average r
2
 ~ 0.4, Supporting Information), 
although this parameter might not reflect the real solubility of the compounds under the assay 
conditions. A slightly better correlation was found with the calculated logP values (average r
2
 
~ 0.5, Supporting Information). These correlations support the contribution of steroid 
lipophilicity to GABAA receptor modulation. However, the contribution from other effects, 
principally arising from the interaction with the receptor, should be invoked to explain the 
observations that an increase of hydrophobicity did not always result on an increase of 
activity (compare 45 vs. 44, 59 vs. 48, 32 vs. 37 or 33 vs. 38), or that compounds very similar 
in hydrophobicity present very disparate activities. That is the case of the isomeric pairs 39 
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and 44, or 24 and 48 which show activities differing by more than one order of magnitude. 
Similarly, the 12-keto isomer of alphaxolone (3) was >20 fold less potent in our flunitrazepam 
binding assays (unpublished results), although their logP values are essentially identical. 
Therefore, in addition to the influence of the global hydrophobicity of the compounds, which 
would affect their partition between the membrane and the intra- and extracellular aqueous 
compartments, these results suggested a dependence of the flunitrazepam binding activity on 
the local lipophobic-lipophilic balance of the groups at the C-ring edge. 
 
 
3D-QSAR analysis 
    A 3D-QSAR approach using the CoMFA and CoMSIA methodologies
55-57 
was devised to 
gain insight into the observed SAR relations. This analysis could only be applied successfully 
to the 5α-neurosteroid series, since including the compounds in the 5β-series or trying to 
obtain a model only for those compounds did not provide significant correlations (see 
Supporting Information). Thus, the best model (CoMSIA-2) was obtained by taking into 
consideration the hydrophobic and electrostatic CoMSIA fields of compounds 1, 3, 12, 13, 15, 
24, 39, 44, 45, 47 to 49, 56, and 59 (see Supporting Information for details). No significant 
improvement was observed by including contributions from the steric, donor and/or acceptor 
fields. Table 2 summarizes the statistical parameters for this model and the correlation 
between experimental and calculated EC50 values. 
    Figure 2a shows the electrostatic and hydrophobic
*
 contour maps from model CoMSIA-2. 
Two main regions are shown for the electrostatic field: one located close to C12 and slightly 
below the steroid plane (B), which reflects a favoured location for groups of the ligand with 
positive electrostatic potential, and one located close to C11 above the steroid plane (R), 
                                                 
*
NOTE: Due to the relatively small number of available compounds and their high structural similarity except at 
the C11-C12 edge, no unfavoured hydrophobic region was clearly defined. 
 12 
which reflects a preferred location for electronegative groups of the ligand. For the 
hydrophobic field, a region is shown close to the C11-C12 edge (G) where the occupation by 
hydrophobic groups of the ligand (i.e. compounds 13, 56 and 59) is favoured. On the same 
figure (Figure 2b-d), the actual electrostatic and hydrophobic fields for ligands 3, 48, and 24 
are also shown. Thus, in addition to several contours that are common to all the compounds 
because of their structural similarity (i.e. close to the 3-OH or the 17-acetyl group), the 
similarly active compounds 3 and 48 show electronegative contours around the 11-carbonyl 
oxygen (R1) and the 11ß-NH2 (R2) which overlap the R region from the model and, therefore, 
contribute to increase the predicted activity of these compounds. The 11-OH group of 
compounds 44 and 45 also yields electronegative contours (data not shown) close to the R 
region, which contribute to their activity. In addition, compound 3 shows a hydrophobic 
region (G1), which partly overlap the favourable contour G from the model and that would 
correlate with its higher activity. On the contrary, the inactive compound 24 shows an 
electronegative contour (R3) close to the 12ß-NH2 group, which overlaps region B of the 
model, where electropositive groups are preferred and therefore it is a main reason for its 
decreased activity. Comparable negative contributions are observed for compounds 12, 15, 
39, 47, and 49. Hence, despite that the results from this 3D-QSAR analysis should be taken as 
preliminary, given the relatively small number of compounds considered, they seem to 
support the hypothesis that at least for the compounds of the 5α-series most of the changes on 
their activity can be explained in terms of the different hydrophobic and electrostatic 
properties at the C11-C12 ring edge of the steroid system, rather than the existence or absence 
of specific interactions with the receptor (other than the basic pharmacophore, ie. a 3α-
hydroxyl and a 20-ketone groups). Based on this, it could be postulated that the region on the 
GABAA receptor, which is complementary to the C-ring edge of the steroids has a 
predominantly hydrophobic character, with residues that tolerate polar substituents only on 
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certain locations, namely regions R and B on Figure 2a. A more non-specific contribution to 
the activity of the compounds could also be expected from variations on their lipophilic 
character, as it has been previously discussed. 
    On the basis of studies that combine results from electrophysiology, molecular biology and 
homology modelling, strong evidence of the existence of a neurosteroid potentiation site 
located on the M1-M4 transmembrane domain of the α-subunit of the GABAA receptor was 
obtained.
48,49
 On this site, residue Q241 would act as hydrogen-bond acceptor capable of 
interacting with the 3α-hydroxyl group of neurosteroids, while residues N407 and Y410 are 
appropriately located to act as hydrogen-bond donors that interact with the C20-keto group. 
These residues are highly conserved in subunit isoforms α1-α5, therefore revealing the 
conserved nature of this potentiation site.
50
  Similarly, a second binding site that spans the 
α,β-subunit interface, implying residues αT236 and βY284, and which is exclusively involved 
in direct receptor activation, was also identified. The existence of additional sites that mediate 
the action of neurosteroids is still a matter of debate.
49,58,59
 Furthermore, the information about 
which other residues may interact at each site with the steroid scaffold or any groups attached 
to it, thus modulating also their binding affinity, is much less clear.
48
 
    Considering that GABAA receptors present an heteropentameric structure formed by 2 α 
and 2 β subunits plus an additional subunit, often a γ subunit, it comes out that each receptor 
must have at least two potentiation sites (at the two α subunits) and two activating sites (at 
two α/β interfaces).48,49,60  Such a large number of potential binding sites hampers the 
elaboration of robust (Q)SAR correlations, since the experimental activity data results from 
the sum of the effects at all sites, added to other non-specific contributions. Therefore, the 
model shown in Figure 2a should be interpreted with care since it might not reflect the real 
nature of a single binding site but rather a combination of the properties required on the ligand 
to effectively develop its biological activity. However, in the absence of further structural 
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details about the receptor, building such correlations can still provide information that could 
be used for the design of new neuroactive steroids with therapeutic potential.  
 
    Conclusions 
 
   A series of 11- and 12-substituted derivatives of 5ξ-pregnanolone were synthesized and 
their binding to the GABAA receptor was measured by in vitro test with [
3
H]-flunitrazepam as 
radioligand. The highest activity among the 5α-series  (EC50 ~1 M) was found in the 
exomethyleno analogue of allopregnanolone 56, while the 11α-phenylethynyl-11-hydroxyl 
derivative 38, with similar EC50, was the most active among the 5β-compounds. Several 
compounds showed activities in the low micromolar range, with EC50 values comparable to 
alphaxolone. Some of them contained modifications that did not alter the local hydrophobicity 
at the C11-C12 edge but others, like 11β-amino derivative 48, did. The SAR/QSAR 
calculations suggest that the changes of activity correlate with the hydrophobic-hydrophilic 
balance at the C-ring edge. 
 
 Experimental  
    Chemistry: Melting points were determined on a Boetius micro melting point apparatus 
(Germany). Optical rotations were measured at 25 
o
C in chloroform using an Autopol IV 
(Rudolf Research Analytical, Flanders, USA, [α]D
 
values are given in 10
-1
.deg.cm
2
.g
-1
). 
Infrared spectra (wave numbers in cm
-1
) were recorded on a Bruker IFS 88 spectrometer. 
1
H 
NMR spectra were taken on Bruker AVANCE-400 instruments (400 MHz, FT mode) at 23 
o
C 
in CDCl3
 
and referenced to TMS as the internal standard. Chemical shifts are given in ppm (δ-
scale); coupling constants (J) and width of multiplets (W) are given in Hz. Thin-layer 
chromatography (TLC), used for monitoring of reactions, was performed on silica gel G (ICN 
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Biochemicals, detection by spraying with concentrated sulfuric acid monitored by heating). 
Preparative TLC (PLC) was carried out on 200 x 200 mm plates coated with a 0.7 mm thick 
layer of the same material. For column chromatography, Silica gel 60 (Merck, 63–100 µ) was 
used. Prior to evaporation on a rotary evaporator in vacuo (0.25 kPa, bath temperature 40 
o
C), 
solutions in organic solvents were dried over anhydrous sodium sulfate. Whenever aqueous 
solutions of hydrochloric acid, potassium hydrogencarbonate, and potassium carbonate were 
used, their concentration was always 5%. Unless otherwise stated, a usual workup means that 
extracts were sequentially washed with the potassium hydrogencarbonate solution and brine, 
dried by filtration through a column of sodium sulfate and evaporated on a rotary evaporator 
in vacuum (bath temperature 50 
o
C).  
    Purity statement 
Purity of all tested compounds possess a purity of at least 95% as documented by TLC and 
combustion analysis. Unless otherwise stated, the structure of the products was confirmed by 
IR and 
1
H NMR spectra. 
 
     (25R)-12-Oxo-5-spirostan-3-yl Methanesulfonate (6). To a cold (0 oC) solution of 
compound 5 (351 mg, 0.81 mmol) in pyridine (10 mL), methanesulfonyl chloride (0.17 mL, 
251 mg, 2.20 mmol) was added dropwise. The reaction was left at 0 
o
C for 2 h, then it was 
quenched with ice, the organics were taken into chloroform, the extract was worked up as 
usual. Mesylate 6 (334 mg, 80%) formed white crystals, mp 176-180 
o
C (chloroform/ligroin). 
[]D -6 (CHCl3, c 0.27). IR: 1711 (CO); 1368, 1345, 1177 (SO2). 
1
H NMR:  0.79 d (3H, 
J=6.7, H-27); 0.93 s (3H, H-18); 1.05 s (3H, H-19); 1.07 d (3H, J=6.7, H-21); 3.00 s (3H, H-
OMs); 3.34 t (1H, J=11, H-26ax); 3.35 m (1H, W=17, H-26eq); 4.33 q (1H, J=5.5, H-16); 
4.60 m (1H, W=32.4, H-3). Anal. (C28H44O6S) C, H, S. 
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    (25R)-12-Oxo-5α-spirostan-3β-yl Toluenesulfonate (7). A solution of hecogenin (5) 
(436.7 mg, 1.01 mmol) in pyridine (10 mL) was cooled to 0 
o
C, and then a solution of 
toluenesulfonyl chloride (577 mg, 3.03 mmol) in pyridine (5.0 mL) was dripped in. After 24 h 
at rt, the reaction was quenched with ice and organics were taken into chloroform. The extract 
was washed with the aqueous solution of hydrochloric acid, potassium hydrogencarbonate, 
and water and dried over sodium sulfate. Evaporation of the solvent yielded tosylate 7 (605 
mg, 96%) as white solid, mp 191-193 
o
C (chloroform/ligroin). []D -4 (CHCl3, c 0.22). IR: 
1711 (CO); 1376, 1178 (SO2). 
1
H NMR:  0.79 d (3H, J=6.6, H-27); 1.03 s (3H, H-18); 0.88 
s (3H, H-19); 1.05 d (3H, J=7.6, H-21); 3.34 t (1H, J=11.0, H-26ax); 3.48 m (1H, W=17.1, 
H-26eq); 4.40 m (H, W=29, H-3); 4.36 q (1H, J=6.7, H-16). Anal. (C34H48O6S) C, H, S.  
    (25R)-3α-Hydroxy-5α-spirostan-12-one (8). Potassium nitrite (112.0 g, 1.31 mol) was 
added while stirring to a warm (130 
o
C) solution of tosylate 7 (25.0 g, 42.80 mmol) in DMF 
(250 mL). After for 2 h, the reaction was quenched with 500 mL of water and left in a 
refrigerator over night. The precipitate was filtered and washed with water. The reaction 
mixture was separated by column chromatography on silica gel. A mixture of toluene/ethyl 
acetate (7%) eluted alcohol 8 (8.3 g, 41.5%) as white crystals, mp 209-211 
o
C. IR: 1702 (CO), 
3616 (OH). []D +15 (CHCl3, c 0.43). 
1
H NMR:  0.79 d (3H, J=6.6, H-27); 0.87 s (3H, H-
18); 1.05 s (3H, H-19); 1.07 d (3H, J=7.6, H-21); 3.35 t (1H, J=10.9, H-26ax); 3.46 m (1H, 
W=18.1, H-26eq); 4.06 s (1H, H-3); 4.36 q (1H, J=6.7, H-16). Anal. (C27H42O4) C, H. 
    (25R)-12-Oxo-5α-spirostan-3α-yl Benzoate (9). Alcohol 8 (8.3 g, 19.27 mmol) was dried 
by azeotropic distillation with benzene, dissolved in pyridine (70 mL), and cooled to 0 
o
C. 
Benzoyl chloride (13.0 mL) was added to a stirred solution during 15 min. After 5 h, the 
reaction was quenched by adding warm water (200 mL, ca 60 
o
C). Benzoate 9 was filtered off 
and washed with the potassium hydrogencarbonate solution. The crude product was dissolved 
in ethyl acetate and dried. Evaporation of the solvent yielded benzoate 9 as white solid 
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(9.28 g, 90%), mp 212-214 
o
C (ether/methanol). IR: 1717, 1274 (OBz). 
1
H NMR:  0.79 d 
(3H, J=6.1, H-27); 0.94 s (3H, H-19); 1.07 s (3H, H-18); 1.08 d (3H, J=7.3, H-21); 3.35 t 
(1H, J=10.4, H-26ax); 3.51 m (1H, W=20.0, H-26eq); 4.35 q (1H, J=4.9, H-16); 5.30 s (1H, 
H-3); 7.55, 7.66, 8.15 (Bz). Anal. (C34H46O5) C, H. 
    (25R)-12β-Hydroxy-5α-spirostan-3α-yl Benzoate (10). Sodium borohydride (2.0 g, 
53.1 mmol) was gradually added to a solution of (25R)-12-oxo-5α-spirostan-3α-yl benzoate 9 
(6.9 g, 12.90 mmol) in ethyl acetate (150 mL) and methanol (100 mL). The reaction was 
monitored quenched after 2 h with 5% HCl. The solvents were evaporated on a vacuum 
evaporator and the organics were taken into ethyl acetate, washed and dried over sodium 
sulfate. Evaporation of the solvent yielded white crystals of compound 10 (5.64 g, 81%), mp 
178-182 
o
C. IR: 3626, 3535 (OH), 3092, 3072, 3064 (BzO), 1717, 1274 (BzO). []D -35.9 
(CHCl3, c 0.26). 
1
H NMR:  0.78 s (3H, H-19); 0.80 d (3H, J=6.7, H-27); 0.87 d (3H, J=2.4, 
H-21); 0.87 s (3H, H-18); 3.37 t (1H, J=11.0, H-26ax); 3.47m (1H, W=18.3, H-26eq); 3.75 dd 
(1H, J=3.8, J=11.0, H-12); 4.41m (1H, W=21.4, H-16); 5.29 s (1H, H-3); 7.46, 7.56, 8.05, 
8.07 H (Bz). Anal. (C34H48O5) C, H.  
    20-Oxo-5α-pregnane-3α,12β-diyl 12-Acetate 3-Benzoate (11). The spirostane derivative 
10 (600 mg, 1.0 mmol) was transferred into a thick glass test tube. Acetic anhydride (2.0 mL) 
and acetic acid (2 drops) were added and the test tube was sealed. The reaction was kept at 
180 
o
C for 24 h. Then it was cooled to –8 oC, and water (0.2 mL), acetic acid (10 mL), and 
dichlorethane (10 mL) were added. A solution of chromium trioxide (200 mg, 2.0 mmol) in 
acetic acid (10 mL) and water (1 mL) was slowly added during 15 min while stirring. After 1 
h, the reaction was quenched with an excess of Na2S2O3 dissolved in water (4 mL). The 
phases were separated, and the aqueous layer was extracted with ether. The extracts were 
washed, dried over a column of sodium sulfate, and concentrated in a vacuum. Finally, the 
remainder was refluxed in acetic acid (10 mL). After 2 h, acetic acid was evaporated on a 
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vacuum evaporator. The remainder was neutralized carefully at 0 
o
C with aqueous NH3. The 
crude intermediate was hydrogenated in toluene (3.0 mL) in the presence of Pd/C (10%, 
50 mg). After 4 h, the catalyst was filtered off and the subsequent preparative chromatography 
of the crude reaction mixture yielded compound 11 (4.8 mg, 9%). IR: 1736, 1247 (Ac); 1717, 
1274 (Bz). 
1
H NMR:  0.85 s (3H, H-19); 0.85 s (3H, H-18); 2.01 s (3H, H-21); 2.08 s (3H, 
Ac); 4.78 dd (1H, J=4.9 and J=11.0, H-12); 5.28 s, (1H, H-3); 7.44, 7.47, 7.51, 7.55, 7.58, 
8.04, 8.07 (Bz). Anal. (C30H40O5) C, H.   
    3α,12β-Dihydroxy-5α-pregnan-20-one (12). Diester 11 (100 mg, 0.21 mmol) was heated 
in a methanolic solution of potassium hydroxide (5%, 10 mL, 8.91 mmol) in nitrogen 
atmosphere. After 6 h, the solution was acidified with hydrochloric acid (6.8 mL, 10.21 
mmol) and concentrated in a vacuum to a quarter of its volume. The concentrate was diluted 
with the potassium hydrogencarbonate solution (5 mL) and the product was extracted with 
chloroform. The extract was worked up yielding a white solid of compound 12 (60 mg, 82%), 
mp 194-197 
o
C (acetone/heptane). [α]D +8 (CHCl3, c 0.26). 
1
H NMR:  0.71 s (3H, H-18); 
0.79 s (3H, H-19); 2.21 s (3H, H-21); 2.43 t (1H, J=8.9, H-17); 3.42 dd (1H, J=10.6 and 5.2, 
H-12); 4.05 m (1H, W=18, H-3). Anal. (C21H34O3) C, H. 
    3α-Hydroxy-5α-pregn-11-en-20-one (13). Acetate 11 (20 mg, 0.04 mmol) was hydrolyzed 
with potassium carbonate (20 mg) in methanol (3 mL) at laboratory temperature. The reaction 
was quenched after 5 h, the organics were extracted with ethyl acetate, washed with water and 
dried over sodium sulfate. The crude product was cooled to 0 
o
C and methanesulfonyl 
chloride (0.2 mL, 0.30 mmol) was slowly added. The reaction mixture was kept at 4 
o
C and 
monitored by TLC (10% ether in benzene). After 12 h, the reaction was quenched with ice, 
the organics were extracted with ethyl acetate, and dried over sodium sulfate. After 
evaporation of the solvent, additional pyridine (5 mL) was added and the reaction was sealed 
in a test tube. Elimination occurred at 180 
o
C. After 24 h, the reaction mixture was diluted 
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with ethyl acetate and washed with 5% HCl. The crude unsaturated benzoate was dissolved in 
a methanolic solution of potassium hydroxide (20 mL, 5%) and stirred for 18 h at laboratory 
temperature. Preparative chromatography yielded white crystals of 13 (8 mg, 56%), mp 148-
150 
o
C (acetone/heptane). []D +111 (c 0.11). 
1
H NMR:  0.68 s (3H, H-18); 0.74 s (3H, H-
19); 2.18 s (3H, H-21); 2.70 t (1H, J=9.2, H-17); 4.08 m (1H, W=12.2, H-3); 5.62 d (1H, 
J=9.2, H-12); 6.11 dd (1H, J=1.8 and 8.5, H-11). Anal. (C21H30O2) C, H.  
    5α-Pregnane-3,12,20-trione (14). Compound 11 (75 mg, 0.20 mmol) was treated with 
lithium aluminum hydride (100 mg) in THF (5.0 mL). After 1 h, the excess reagent was 
carefully quenched with water. The resulting mixture was dissolved in acetic acid (5 mL) and 
chromium trioxide (40 mg) was added. The oxidation, complete after 2 h (TLC), was 
quenched with sodium sulfite. The crude organics were extracted with ethyl acetate, washed, 
and dried. The remainder after evaporation was purified by chromatography (benzene/ether, 
4:1) to yield triketone 14 (53 mg, 80%) as white solid, mp 210-212 
o
C (AcOEt), Shimizu
61
 
gives 208-212 
o
C. IR: 1652, 1701 (CO). 
1
H NMR:  0.72 s (3H, H-18); 0.78 s (3H, H-19); 
2.14 s (3H, H-21).   
    3α,12α-Dihydroxy-5α-pregnan-20-one (15). In a sealed tube, triketone 14 (50 mg, 0.15 
mmol) was heated with a solution of hydrogen hexachloroiridate hydrate (5 mg, 0.01 mmol) 
and phosphorous acid (50 mg, 0.61 mmol) in water (0.3 mL) and 2-propanol (1.5 mL) at 90 
o
C. After 10 h, potassium carbonate (50 mg, 0.36 mmol) was added and the mixture was 
concentrated in a vacuum. The mixture was diluted with brine and extracted with ethyl 
acetate. After the usual work-up, the product was purified using thin layer chromatography on 
silica gel (toluene/ethyl acetate). Extraction of the major zone yielded diol 15 (29 mg, 58%) 
as white crystals, mp 201-202 
oC (acetone/heptane); [α]D +165 (CHCl3, c 0.16). IR: 3616, 
1005 (OH); 1702, 1362 (COCH3). 
1
H NMR:  0.87 s (3H, H-18); 0.95 s (3H, H-19); 2.27 s 
(3H, H-21); 3.32 t (1H, J=9.1, H-12); 4.10 m (1H, W=16.8, H-3). Anal. (C21H34O3) C, H. 
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       (25R)-3α-Hydroxy-12-oximino-5α-spirostane (16). Hydroxylamine hydrochloride 
(1.5 g, 21.70 mmol) was added to a solution of compound 8 (1.13 g, 2.62 mmol) in pyridine 
(10 mL), the mixture was stirred at 60 
o
C for 1 h (the reaction was monitored by TLC 
developed with 3% of methanol in ammoniacal chloroform). The usual workup yielded oxime 
16 (1.11 g, 95%) as white solid, mp 264-266 
o
C, IR: 3616 (OH); 3592, 3367 (NOH); 1644 
CN. []D +12 (CHCl3, c 0.11). 
1
H NMR:  0.79 d (3H, J=6.1, H-27); 0.85 s (3H, H-18); 0.96 s 
(3H, H-19); 1.05 d (3H, J=7.3, H-21); 3.34 t (1H, J=11.0, H-26ax); 3.35 m (1H, W=17, H-
26eq); 4.06 m (1H, W=17, H-3); 4.37 q (1H, W=30, H-16). Anal. (C27H43NO4) C, H, N. 
 
    (25R)-12-Amino-5α-spirostan-3α-ol (17) and (25R)-12-amino-5α-spirostan-3α-ol 
(18). Sodium borohydride (167 mg) was added to a solution of oxime 16 (40.7 mg, 
0.09 mmol) and molybdenum trioxide (55 mg) in methanol (5 mL). The reaction mixture 
turned black immediately. The reaction, followed with TLC (1% methanol in ammoniacal 
chloroform), was quenched with 10 mL of water. Methanol was evaporated on a vacuum 
evaporator, the organics were extracted with ammoniacal chloroform, and dried. Analysis of 
1
H NMR spectra of the reaction mixture revealed that the product (35 mg, 89%) consisted of a 
1.2:1 mixture of 12α-and 12ß-amine 17 and 18, resp. Chromatography yielded:  
12-amine 17 (18 mg, 49%), []D -9 (CHCl3, c 0.09). IR: 3616, 3455 (OH); 3387, 1614, 839 
(NH2). 
1
H NMR:  0.79 d (3H, J=6.1, H-27); 0.78 s (3H, H-18); 0.85 s (3H, H-19); 0.97 d 
(3H, J=6.7, H-21); 2.78 s (1H, H-12); 3.37 t (1H, J=11.0, H-26ax); 3.47 m (1H, W=16, H-
26eq); 4.03 s (1H, H-3); 4.37 m (1H, W=28, H-16). Anal. (C27H45NO3) C, H, N.  
12 amine 18 (16 mg, 40%), []D -33 (CHCl3, c 0.13). IR: 3615, 3453 (OH); 3384, 1610, 842 
(NH2). 
1
H NMR:  0.71 s (3H, H-18); 0.79 s (3H, H-19); 0.79 d (3H, J=6.1, H-27); 1.05 d 
(3H, J=6.1, H-21); 2.46 dd, (1H, J=3.7, J=11.0, H-12); 3.36 t (1H, J=11.0, H-26ax); 3.46 m 
(1H, W=17, H-26eq); 4.03 s (1H, H-3); 4.42 q (1H, J=22.0, H-16). Anal. (C27H45NO3) C, H, 
N.   
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    3α-Hydroxy-12β-acetamino-5α-pregnan-20-one (19). The above 12β-aminospirostane 
derivative 18 (100 mg, 0.23 mmol) was converted into a 5α-pregnane derivative as described 
in the conversion of compound 10 to 11. The product was hydrolyzed with methanolic 
potassium carbonate (10 mL, 10%). The reaction yielded compound 19 (24 mg, 30%) as 
white solid, mp 296-298 
o
C (ether). []D +16 (CHCl3, c 0.36). IR: 3615, 1003 (OH); 3446, 
1667, 1504 (CONH); 1698 (C=O). 
1
H
 
NMR:  0.74 s (3H, H-18), 0.78 s (3H, H-19), 2.08 s 
(3H, H-21), 2.10 s (3H, Ac), 2.83 t (1H, J=9.2, H-17), 4.07 m (1H, W=18.7, H-3); 4.40 m 
(1H, W=26.3, H-12); 5.82 m (1H, NH). Anal. (C23H37NO3) C, H, N.  
   12,20-Dioxo-5α-pregnan-3β-yl Acetate (20). Hecogenin (5, 10.1 g, 23.45 mmol) was 
treated with acetic anhydride (250 ml), oxidized, and refluxed in acetic acid as in the 
preparation of compound 11. The raw product was hydrogenated in ethyl acetate (150 mL), 
using palladium on carbon (10%, 400 mg) at laboratory temperature. After 2 h, the catalyst 
was removed and the solvent evaporated, yielding saturated product 20 (3.3 g, 38%) as white 
crystals, mp 193-194 
o
C (ethyl acetate, reference
62 
gives 192-193.5 
o
C). IR: 1708, 1737 CO. 
[]D +139 (CHCl3, c 0.23). 
1
H NMR:  0.91 s (3H, H-19); 0.95 s (3H, H-18); 2.02 s, (3H, H-
21); 2.26 s (3H, Ac); 2.49 t (1H, J=13, H-17); 3.31 t (1H, J=9.3, H-11); 4.68 m (1H, W=32, 
H-3).    
     N-(12β-t-Butyloxycarbonyl)-amino-20-oxo-5α-pregnan-3β-yl Acetate (21). 12,20-
Dioxo derivative 20 (362 mg, 0.97 mmol) was dissolved in hot 2-methyl-2-propanol (12 mL) 
while stirring. Ammonium acetate (1.8 g, 15.1 mmol) and sodium cyanoborohydride (130 mg, 
2.0 mmol) were added and the mixture was allowed to cool to laboratory temperature. After 3 
h, the mixture was diluted with chloroform (60 mL), the extract was washed with brine and 
dried. The solvent was removed in vacuum, the remainder was dissolved in toluene and 
applied on a short column of silica gel (6 mL). A mixture of toluene and ether (1:1, 40 mL) 
eluted a neutral admixture (69 mg), while ammoniacal chloroform (60 mL) eluted a mixture 
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of 12-amino 20-alcohols (328 mg, 0.87 mmol). The mixture was dissolved in pyridine (1.0 
mL) and toluene (1.0 mL), and treated with a solution of di-tert-butyl dicarbonate (350 mg, 
1.6 mmol) in toluene (1.0 mL) at laboratory temperature. After 15 min, the mixture was 
washed with the solution of potassium hydrogencarbonate and water, and dried. After 
evaporation of the solvent, the product was dissolved in acetone (2.5 mL) and oxidized with 
Jones reagent at 0 
o
C. After 3 min, the reaction was stopped with the solution of potassium 
hydrogencarbonate and the product was extracted with ether, washed with water, and dried. 
PLC yielded 293 mg (81%) of ketone 21 as white crystals, mp 95-98 
o
C  (acetone/heptane). 
[α]D +44 (CHCl3, c=0.2). IR 3444, 3387, 1707, 1169 (NH-CO); 1725, 1360, 1029 (AcO). 
1
H 
NMR:  0.76 s (3H, H-18); 0.81 s (3H, H-19); 1.41 s (9H, BOC); 2.02 s (3H, AcO); 2.13 s 
(3H, H-21); 2.72 t (1H, J=9.8, H-17); 3.46 m (1H, W=28.0, H-12α); 4.70 m (1H, W=38.1, H-
3). Anal. (C28H45NO5) C, H, N.  
    N-(12β-t-Butyloxycarbonyl)-amino-3β-hydroxy-5α-pregnan-20-one (22). A solution of 
potassium carbonate (80 mg, 0.58 mmol) in water (0.4 mL) was added into a solution of 
acetate 21 (248 mg, 0.52 mmol) in methanol (20 mL). The mixture was stirred at 50 
o
C for 3 
h. The reaction mixture was concentrated in vacuum to a quarter of its volume, brine was 
added to precipitate the product (224 mg, 99%), which was purified by PLC (toluene/ether, 
1:1). The major product 22 (189 mg, 84%) forms white crystals, mp 177-178 
o
C 
(acetone/heptane). [α]D +57 (chloroform, c=0.24). IR: 3444, 3387 (NH); 1725, 1029 (AcO); 
1707, 1360, 1169 (N-C=O and R2C-O). 
1
H NMR:  0.76 s (3H, H-18); 0.79 s (3H, H-19); 
1.41 s (9H, BOC); 2.13 s (3H, H-21); 2.72 t (1H, J=9.8, H-17); 3.45 m (1H. (W=29.8, H-12α); 
3.59 m, 1H (W=34.9, H-3), 4.72 d, 1H (J =8.8, N-H). Anal. (C26H43NO4 ) C, H, N. 
    N-(12β-t-Butyloxycarbonyl)-amino-3α-hydroxy-5α-pregnan-20-one (23). 3β-Alcohol 
22 (244 mg, 0.56 mmol) was dried by distillation with toluene, dissolved in pyridine (0.6 mL) 
and the solution was stirred at 0 
o
C. Methanesulfonyl chloride (0.3 mL, 3.9 mmol) was 
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dripped in within 2 min. After 2 h at the same temperature, the mixture was decomposed with 
ice and product was extracted with chloroform. The extract was washed with the aqueous 
solutions of hydrochloric acid, water, and potassium hydrogencarbonate. The solution was 
dried and concentrated in vacuum. The remainder was treated with sodium nitrite (750 mg, 
10.9 mmol) in HMPA (5 mL) at 90 
o
C under argon. After 4 h, the mixture was cooled, poured 
onto brine, and precipitate was extracted with ethyl acetate. The extract was washed, dried, 
and concentrated in vacuum as usual. The product was purified by PLC (6 plates, 
toluene/ether, 3:1), the major zone was eluted with ether yielding the title compound 23 (146 
mg, 60%) as white crystals, mp 154-155 
o
C (acetone/heptane). [α]D +53 (chloroform, c=0.2). 
IR: 3616, 1001 (OH); 3444, 3388, 1503 (NHCO); 1705 (C=O); 1393, 1367 (tert-Bu). 
1
H 
NMR:  0.76 s (6H, H-18 and H-19); 1.41 s (9H, BOC); 2.13 s (3H, H-21); 2.74 t (1H, J=9.9, 
H-17); 3.49 m (1H, W=32.0, H-12α); 4.03 m (1H, W=20.0, H-3), 4.69 d (1H, W=26, N-H). 
Anal. (C26H43NO4) C, H, N.  
    12β-Amino-3α-hydroxy-5α-pregnan-20-one (24) Trifluoroacetic acid (0.4 mL, 5.2 mmol) 
was dripped into a solution of the BOC-derivative 23 (65 mg, 0.15 mmol) in aqueous acetone 
(50%, 2.0 mL). After 1 h, the mixture was concentrated in vacuum and alkalized with 
ammonia (3.0 mL). The product was extracted with chloroform, washed with water, dried, 
and applied onto two PLC plates. The plates were developed with ammoniacal CHCl3/propan-
2-ol, 95/5. The major zone was eluted with ethyl acetate which yielded amine 24 (45 mg, 
90%) as colourless solid, mp 134-136 
o
C (chloroform/heptane). [α]D +6 (c 0.10). IR: 3616, 
999 (OH); 3376, 3309, 1603 (NH2); 1700, 1358, 597 (C=O). 
1
H NMR:  0.72 s (3H, H-18); 
0.77 s (3H, H-19); 2.25 s (3H, H-21); 2.54 t (1H, J=9.7, H-17); 2.58 dd (1H, J=11.2 and 4.3, 
H-12α); 4.04 m (1H, W=19.7, H-3). Anal. (C21H35NO2) C, H, N.  
    11α-Hydroxy-5-pregnane-3,20-dione (26) 11α-Hydroxyprogesterone (25, 2.1 g, 6.36 
mmol) was hydrogenated in pyridine (15 mL) in the presence of palladium on carbon (10%, 
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180 mg). After 5 h, the catalyst was filtered off and the solvent was evaporated in a vacuum. 
On addition of ether (10 mL) to the remainder, crystals of a mixture of 5-dihydro derivatives 
(505 mg) were swiftly formed. Recrystallization from ethyl acetate yielded the 5-dihydro 
product 26 (333 mg, 16%). Additional product (1.54 g, 73%) was obtained by 
chromatography of mother liquor on silica gel with toluene/ether, 1:1, mp 173-175 
o
C 
(acetone/heptane). []D +103 (c 0.3) (Mancera
32
 gives 169-171 
o
C and +105). 
1
H NMR:  
0.66 (s, 3H, H-18); 1.14 (s, 3H, H-19); 2.14 (s, 3H, H-21); 2.57 (t, 1H (J=9.0, H-17); 3.99 (m, 
1H (W=36, H-11);. HRMS (ESI): M
-
 found 331.2267; for C21H32O3 calc.331.2273.  
    11α-Hydroxy-5α-pregnane-3,20-dione (27). The side product of the above 
chromatography was identified as the 5α-isomer 27 (95 mg, 5%), mp 188-192 oC 
(acetone/heptane; Peterson
33
 gives 198-201 
o
C). 
    3α,11α-Dihydroxy-5-pregnan-20-one (28). Sodium borohydride (5.5 mg, 0.15 mmol) 
was added to a solution of diketone 26 (73 mg, 0.22 mmol) in methanol (0.2 mL) and pyridine 
(1.8 mL) under stirring at 0 
o
C. After 2 h, the mixture was kept at laboratory temperature for 
18 h. Excess reagent was destroyed with hydrochloric acid (5%, 8 mL), the solvents were 
partly evaporated in a vacuum and brine was added. Product was extracted with ethyl acetate, 
the extract was washed with brine, dried and concentrated in a vacuum. TLC (2 plates) was 
run in toluene/ethyl acetate, 1:3. The most lipophilic component (5 mg, 7%) was the 3-
isomer, the most polar component (6 mg, 8%) was the 17α-isomer. The major component, 
compound 28 (52 mg, 71%), was obtained as white crystals, mp 180-181 
o
C (acetone/heptane, 
reference
34
 gives 181.4 - 182.4 
o
C). []D +82 (c 0.3).  
1
H NMR:  0.61 s, 3H (H-18); 1.05 s, 
3H (H-19); 2.13 s, 3H (H-21); 2.56 t, 1H (J=8.8, H-17); 3.70 m, 1H (W=32, H-3); 3.88 dt, 1H 
(J=10.2 and 5.1, H-11). 
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    3,3,20,20-Bisethylenedioxy-5-pregnan-11-one (29) was prepared by oxidation and 
ketalisation of ketone 26 according to Kalvoda
35
. 
1
H NMR:  0.71 s, 3H (H-18); 1.17 s, 3H 
(H-19); 1.25 s, 3H (H-21); 1.31 t, 1H (J=7.2, H-17), 3.93 m, 8H, W=59.4, (CH2O)2.   
    20,20-Ethylenedioxy-5-pregnane-3,11-dione (30) was prepared by ketalisation and 
oxidation of ketone 28 according to Mancera
32
. 
1
H NMR:  0.74 s (3H, H-18); 1.24 s (3H, H-
19); 1.26 s (3H, H-21); 3.89 m (2H, W=36.1, OCH2); 3.97 m (2H, W=32.8, OCH2). 
 
    General Method for the Grignard Reaction. A solution of the Grignard reagent in THF 
(0.5M, 24 mL, 12 mmol) was added to a ketone (1.20 mmol) under stirring. The reaction 
mixture, monitored by TLC, was kept at 65 
o
C for 10-18 h. When complete, the mixture was 
poured into a saturated aqueous ammonium chloride solution. The precipitate was extracted 
with ether, washed with brine, and dried over magnesium sulfate. The solvent was evaporated 
and the residue was purified by preparative thin-layer chromatography:     
     3,11-Dihydroxy-5-pregnan-20-one (31) was prepared from ketal 30 by reduction 
with LAH in THF and deprotection according to ref.
35
. 
1
H NMR:  0.84 (s, 3H, H-18); 1.17 
(s, 3H, H-19); 2.12 (s, 3H, H-21); 2.46 (t, J=8.9, H-17); 3.69 (m, W=38 Hz, 1H, H-3); 4.26 
(m, 1H, W=18, H-11). 
    3,11-Bis-ethynyl-3,11-dihydroxy-5-pregnan-20-one (32). Following the general 
procedure, 20,20-ethylenedioxy-5-pregnane-3,11-dione (ref.,16 30, 80 mg, 0.22 mmol) was 
treated with ethynyl magnesium bromide (0.5 M solution in THF,  40 mL) for 16 h. After the 
usual work up and chromatography (toluene/ethyl acetate, 6:4), the ketal obtained was 
hydrolyzed in position 20 by the treatment with p-toluenesulfonic acid (15 mg) in acetone (15 
mL) at 55
 o
C for 15 min. The usual work up and chromatography on two preparative plates 
(toluene/ethyl acetate, 6:4) gave compound 32 (25 mg, 30%) as white crystals, mp 235-238 
o
C (acetone/heptane). []D +109 (CHCl3, c 0.2). IR: 3594, 1106 (OH); 3305, 2223, 651 
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(CC); 1702, 594 (CO). 1H NMR:  0.81 (s, 3H, H-18); 1.26 (s, 3H, H-19); 2.13 (s, 3H, H-
21); 2.50 (s, 1H, H-CC) and 2.53 (s, 1H, H-CC). Anal. (C25H34O3) C, H. 
    3,11-Dihydroxy-3,11-bis-phenylethynyl-5-pregnan-20-one (33). Following the 
general procedure, ketal 30 (100 mg, 0.27 mmol) was treated with phenylethynyl magnesium 
bromide (1.0 M solution in THF, 2.4 mL) for 10 h. After the usual work up and deprotection, 
chromatography (elution with toluene/ethyl acetate, 6:4) gave compound 33 (49 mg, 34%) as 
white crystals, mp 220-222 
o
C (acetone/heptane). []D +33 (CHCl3, c 0.1). IR: 3593, 1105 
(OH); 2223 (CC); 1701,1356, 594 (CO); 1490, 1444, 1329, 1028, 692 (phenyl). 1H NMR:  
0.86 (s, 3H, H-18); 1.32 (s, 3H, H-19); 2.16 (s, 3H, H-21); 7.31 (m, 5H, phenyl), and 7.37 (m, 
5H, phenyl). Anal. (C37H42O3) C, H. 
   3-Hydroxy-5-pregnane-11,20-dione (34). Ketal 30 (90 mg, 0.24 mmol) was reduced 
with sodium borohydride in pyridine and deprotected as in the preparation of compound 28 
PLC yielded white crystals of compound 34 (31 mg, 39%), mp 172-174 
o
C (acetone/heptane. 
Mancera
32
 gives 168-171 
o
C). 
1
H NMR:  0.57 (s, 3H, H-18); 1.15 (s, 3H, H-19); 2.10 (s, 3H, 
H-21); 2.47 and 2.57 (2H, AB system, J=11.5, H-12); 2.76 (t, 1H, J=9.1, H-17); 3.65 (m, 1H, 
W=36, H-3). 
    11-Ethynyl-11-hydroxy-5-pregnane-3,20-dione (35). Following the general 
procedure, 3,3,20,20-bisethylenedioxy-5-pregnan-11-one (29, 0.5 g, 1.20 mmol) was treated 
with ethynyl magnesium bromide (0.5 M solution in THF, 24 mL, 12 mmol) for 18 h. The 
product was deprotected by treatment with p-toluenesulfonic acid (30 mg) in acetone (30 mL) 
at 55
 o
C for 15 min. The usual work up and chromatography (elution with toluene/ethyl 
acetate, 7:3) gave compound 35 (102 mg, 24%) as white crystals. mp 192-195 
o
C 
(acetone/heptane). []D +150 (CHCl3, c 0.1). IR: 3627, 3593, 1112 (OH); 3303, 2103, 637 
(CC); 1703, 1422, 1359, 594 (CO). 1H NMR:  1.00 (s, 3H, H-18); 1.45 (s, 3H, H-19); 2.28 
(s, 3H, H-21); 2.69 (s, 1H, H-CC). Anal. (C23H32O3) C, H.  
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    11-Hydroxy-11-phenylethynyl-5-pregnane-3,20-dione (36). Analogously, ketone 29 
(0.5 g, 1.20 mmol) was treated with phenylethynyl magnesium bromide (1.0 M solution in 
THF, 12 mL, 12 mmol) for 10 h and deprotected as above. After the usual work up and 
chromatography (toluene/ethyl acetate, 9:1), compound 36 (145 mg, 28%) was obtained as 
white crystals, mp 181-183 
o
C (acetone/heptane). []D +190 (CHCl3, c 0.2). IR: 3593, 1112, 
1236 (OH); 2220 (CC); 1703, 594 (CO); 1491, 1444, 1161, 691 (phenyl). 1H NMR:  0.90 
(s, 3H, H-18); 1.35 (s, 3H, H-19); 2.16 (s, 3H, H-21); 2.72 (t, 1H, J=14.4, H-5); 7.32 (m, 5H, 
phenyl).  Anal. (C29H36O3) C, H. 
    11-Ethynyl-3,11-dihydroxy-5-pregnan-20-one (37) . A solution, prepared from 
methanol (1.5 mL), a methanolic solution of sodium hydroxide (2.5 N,  0.05 mL) and  a 
pyridine solution of sodium borohydride (0.18 M, 1.4 mL), was added to a solution of 
diketone 35 (61 mg, 0.17 mmol) in methanol (4.5 mL) at 0 
o
C under nitrogen. After 10 min, 
an excess of hydrochloric acid was added and the solution was extracted with ether. The 
extract was washed with an aqueous solution of potassium hydrogencarbonate, water, and 
dried over sodium sulfate. Evaporation of the solvent and chromatography of the residue on 
three preparative plates (toluene/ethyl acetate, 6:4) gave compound 37 (40 mg, 66%), mp 195-
197 
o
C (acetone/heptane). []D +133 (CHCl3, c 0.1). IR: 3599, 3457, 1030, 1115 (OH); 1701, 
1359, 593 (CO); 3304, 2105, 636 (CC). 1H NMR:  0.81 (s, 3H, H-18); 1.22 (s, 3H, H-19); 
2.14 (s, 3H, H-21); 2.53 (s, 1H, H-CC); 3.72 (m, 1H, W=32, H-3). Anal. (C23H34O3) C, H.  
   3,11-Dihydroxy-11-phenylethynyl-5-pregnan-20-one (38). Diketone 36 (74 mg, 
0.17 mmol) was reduced in position 3 as described above. Compound 38 (46 mg, 62%) forms 
white crystals. mp 199-202 
o
C (acetone/heptane). []D +207 (CHCl3, c 0.1). IR: 3603, 1235, 
1114 (OH); 2222 (CC); 1700, 1358, 594(CO); 1491, 1448, 1179, 1164, 1073, 1029, 691 
(phenyl). 
1
H NMR:  1.00 (s, 3H, H-18); 1.40 (s, 3H, H-19); 2.30 (s, 3H, H-21); 3.87 (m, 1H, 
W=31, H-3); 7.43 and 7.52 (2x m, 5H, phenyl). Anal. (C29H38O3) C, H. 
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    3α,11α-Dihydroxy-5α-pregnan-20-one (39). Diketone 27 (85 mg, 0.26 mmol) was treated 
with hydrogen hexachloroiridate hydrate and 2-propanol as in the preparation of compound 
15. The product was purified by PLC, the major component was identified as the diol 39 
(ref.
63
,
 
40 mg, 47%). 
1
H NMR:  0.62 (s, 3H, H-18); 0.93 (s, 3H, H-19); 2.13 (s, 3H, H-21); 
2.56 (t, 1H, J =8.0, H-17); 3.92 (m, 1H, W=36, H-11); 4.02 (m, 1H, W=16, H-3).  
    11,20-Dioxo-pregna-3,5-dien-3-yl Acetate (40) was prepared from 11α-
hydroxyprogesterone (25) according to ref.
36
 
1
H NMR:  0.63 (s, 3H, H-18); 1.19 (s, 3H, H-
19); 2.12 (s, 3H, H-21); 2.13 (s, 3H, OAc); 2.70 (t, 1H, J=9.0, H-17); 5.35 (m, 1H, W=7.3, H-
4); 5.68 (m, 1H, W=2.0, H-6).  
    3-Hydroxy-5α-pregnane-11,20-dione (41). Enol acetate 40 (6.0 g, 16.2 mmol) was 
hydrogenated in a mixture of ethanol (200 mL) and ethyl acetate (50 mL) in the presence of 
palladium on charcoal (2.5 g, 10%). The product was dissolved in methanol (300 mL) and 
boiled with a solution of potassium carbonate (6.0 g, 43.4 mmol) in water (30 mL). After 1 h, 
acetic acid was added (5 mL) and the solvent was partly evaporated in a vacuum and the 
product precipitated after addition of water. Flash chromatography of the product on silica gel 
in a mixture of toluene/ether, 4:2 yielded compound 41 (2.2 g, 41%) as white crystals, mp 
192-194 
o
C (acetone/heptane, Djerassi
64
 recorded the same value). 
1
H NMR  0.57 (s, 3H, H-
18); 1.01 (s, 3H, H-19); 2.09 (s, 3H, H-21); 2.71 (t, 1H, J=9.2, H-17); 3.57 (m, 1H, W=35.4, 
H-3).  
     11,20-Dioxo-5α-pregnan-3-yl Mesylate (42). Methanesulfonyl chloride (4 mL, 51.7 
mmol) was slowly added to a cold (0 
o
C) solution of compound 41 (2.1 g, 6.3 mmol) in 
pyridine (8 mL) under stirring. After 2 h, crushed ice and water (50 g) was added. After 2 h, 
solid was filtered off, washed with water, and dissolved in CH2Cl2. The extract was dried over 
sodium sulfate and concentrated in a vacuum. On addition of ether, compound 42 (2.1 g, 
81%) crystallized as white needles, mp 155-156 
o
C, []D +86 (c 0.4, CHCl3). IR (CHCl3): 
 29 
1704 (C=O); 1357, 1172, 935, 926 (MsO). 
1
H NMR:  0.57 (s, 3H, H-18); 1.03 (s, 3H, H-19); 
2.10 (s, 3H, H-21); 2.72 (t, 1H, J=9.1, H-17); 3.00 (s, 3H, Ms); 4.60 (m, 1H, W=33.1, H-3). 
Anal. (C22H34O5S) C, H, S.  
    3α-Hydroxy-5α-pregnane-11,20-dione (3). Mesylate 42 (2.05 g, 5.0 mmol) was 
solvolyzed as in the preparation of compound 8. The mixture was separated using column 
chromatography, the major fraction (0.93 g, 56%) crystallized from acetone, mp 170-171 
o
C. 
[]D +97 (c 0.2).   (Nagata
65
 recorded 172 
o
C and +113.4). 
1
H NMR:  0.57 (s, 3H, H-18); 
1.00 (s, 3H, H-19); 2.10 (s, 3H, H-21); 2.57 and 2.50 (AB system, 2H, J=11.6, 2H-11); 2.73 
(t, 1H, J =9.0, H-17); 4.05 (m, 1H, W=8.0, H-3). 
   20,20-Ethylenedioxy-3α-hydroxy-5α-pregnan-11-one (43). Diketone 3 was converted 
into its mono ketal 43 (ref.
66
) as described above. IR: 3616, 3492, 999 (OH); 1700 (C=O).  
1
H 
NMR:  0.71 (s, 3H, H-18); 1.00 (s, 3H, H-19); 1.25 (s, 3H, H-21); 2.02 (t, J=9.5, H-17); 3.87 
(m, W=28.5, 4H, OCH2CH2O); 3.96 (m, W=25.0, 4H, OCH2CH2O); 4.03 (m, 1H, W=14.0, H-
3). 
   3α,11-Dihydroxy-5α-pregnan-20-one (44). Ketal 43 (120 mg, 0.36 mmol) was treated 
with LAH in THF as in the preparation of compound 31. After deprotection and PLC 
purification, diol 44 (85 mg, 70%) was obtained as white crystals, mp 202-204 
o
C 
(acetone/heptane; ref.
67
 records 204-206 
o
C). 
1
H NMR:  0.84 (s, 3H, H-18); 1.03 (s, 3H, H-
19); 2.12 (s, 3H, H-21); 2.43 (t, J=9.2, H-17); 4.06 (m, 1H, W=14.0, H-3), 4.40 (m, 1H, 
W=14.0, H-3).  
   11α-Ethynyl-3α,11-dihydroxy-5α-pregnan-20-one (45) Ketal 43 (65 mg, 0.20 mmol) 
was treated with a solution of ethynylmagnesium bromide (0.5 M solution in THF,  6 mL) for 
16 h as in the preparation of compound 32. After deprotection and PLC purification, diol 45 
(23 mg, 33% or 90% after allowance for the recovered starting material) was obtained as 
white crystals, mp 150-152 
o
C (aqueous alcohol). IR (CHCl3): 3615, 3596, 1050, 1000 (OH); 
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3305, 640, 620 (CC); 1700, 593 (C=O). []D +94 (c 0.1). 
1
H NMR:  0.80 (s, 3H, H-18); 
1.08 (s, 3H, H-19); 2.14 (s, 3H, H-21); 2.46 (t, J=9.4, H-17); 2.59 (s, 1H, H-CC); 4.03 (m, 
1H, W=14.0, H-3). HRMS (ESI), m/z calcd. for C23H34O3Na: 381.2400; found: 381.2390. 
Anal. (C23H34O3) C,H. 
  
   20,20-Ethylenedioxy-11-oximino-5α-pregnan-3α-ol (46). Compound 43 (618 mg, 1.64 
mmol) was added to a solution of NH2OH.HCl (2.11 g, 30.3 mmol) and KOH pellets (2.58 g, 
39.1 mmol) in EtOH (15 mL) and the mixture was heated in a sealed tube at 85 
o
C. After 5 d, 
the reaction mixture was diluted with brine (50 mL), ethanol was removed in vacuum on a 
rotary evaporator, and product was extracted with chloroform. Amorphous product consisting 
of crude oxime 46 (523 mg, 81%) was used as such without purification. IR (CHCl3): 3616, 
1002 (OH); 3594 (C=NOH). 
1
H NMR:  0.71 (s, 3H, H-18); 1.05 (s, 3H, H-19); 1.33 (s, 3H, 
H-21); 3.92 (m, 4H, W=58.0, ketal); 4.03 (m, 1H, W=14.0, H-3); 7.18 (m, 1H, oxime). 
   11α-Amino-3α-hydroxy-5α-pregnan-20-one (47). Sodium (1.4 g, 60.9 mmol) was added 
stepwise to a boiling solution of oxime 46 (75 mg, 0.19 mmol) in 2-propanol (15 mL). After 2 
h, the excess sodium was decomposed with 2-propanol, the mixture was concentrated in 
vacuum, diluted with brine, and extracted with chloroform. The extract was washed, dried and 
concentrated in vacuum as usual. A mixture of THF (3 mL) and dilute hydrochloric acid (5%, 
0.2 mL) was used to de-protect the ethylenedioxy intermediate. After 2 h, ammonia (2 mL) 
was added, solvents were evaporated and the remainder purified by  TLC (CHCl3 pretreated 
with ammonia, two elutions). The most polar component consisted of compound 47 (31 mg, 
49%), mp 110-113 
o
C (acetone/heptane). []D +28 (c 0.2). 
1
H NMR:  0.61 (s, 3H, H-18); 
0.93 (s, 3H, H-19); 2.13 (s, 3H, H-21); 2.53 (t, 1H, J=8.8, H-17); 3.04 (m, 1H, W=33.6, H-
11); 4.02 (m, 1H, W=16.0, H-3). MS-ESI: M
+
 334.2. Anal. (C21H35NO2) C, H, N. 
   11-Amino-3α-hydroxy-5α-pregnan-20-one (48). Within 2 h, sodium borohydride (120 
mg, 3.17 mmol) was added in portions to a slurry of oxime 46 (38 mg, 0.1 mmol) and MoO3 
 31 
(100 mg, 0.78 mmol) in MeOH (2.0 mL) while stirring at laboratory temperature. After 
additional 2 h, the mixture was alkalized with a solution of KOH (66 mg, 1.18 mmol) in water 
(0.7 mL) at laboratory temperature. After 18 h, inorganic material was filtered off and washed 
with methanol. The filtrate was concentrated in vacuum, the remainder was treated with 
hydrochloric acid (5%, 0.3 mL) in THF (3 mL) to free the protecting group. After addition of 
ammonia (6 mL), volatile components were evaporated in vacuum and the remainder was 
purified by TLC (chloroform pretreated with ammonia/2-propanol, 96:4). The most polar 
component 48 (13 mg, 40 mmol) formed white crystals (MeOH/H2O), mp 153-156 
o
C. [α]D  
113.7 (c 0.3). IR: 3615, 3444, 1002 (OH); 1700, 1358, 594 (C=O); 3412, 1623, 1237 (NH2). 
1
H NMR:  0.85 (s, 3H, H-18); 1.02 (s, 3H, H-19); 2.13 (s, 3H, H-21); 2.45 (t, 1H, J=9.0, H-
17); 3.60 (m, 1H, W=21.4, H-11); 4.06 (m, 1H, W=19.0, H-3). HRMS (ESI): M
+
 calc. 
334.2741; found: 334.200. Anal. (C21H35NO2.H2O) C,H,N. 
    3α-Hydroxy-11α,12α-oxido-5α-pregnan-20-one (49). Standard oxidation of olefin 13 (46 
mg, 0.14 mmol) with 4-chloroperoxybenzoic acid (30 mg in 2 ml of chloroform) gives a 
single product (49) which was purified with TLC (toluene/ether, 2+1), mp 166-168 
o
C 
(acetone/heptane). Anal. (C21H32O3) C,H. 
   3,3,20,20-Bis-ethylenedioxy-5-pregnan-11-one (50). 5-Pregnane-3,11,20-dione (1.28 g, 
3.87 mmol) was treated with ethylene glycol and p-toluenesulfonic acid in toluene as in the 
preparation of compound 29, mp 205-206 
o
C (ref.
23
 records 207-210 
o
C). []D +50 (c 0.2). IR 
(CHCl3): 1701 (C=O); 1100, 1074, 1056, 948 (OCH2CH2O).  
1
H NMR:  0.71s (3H, H-18); 
1.02 s (3H, H-19); 1.25 s (3H, H-21); 2.02 t (1H, J=9.7, H- 17α); 2.25 d and 2.58 d (2H, AB 
system, J=12.4, H-12), 3.92 m (8H, W=73.7, ethylene dioxy groups). 
3,3,20,20-Bis-ethylenedioxy-11α-methyl-5-pregnan-11-ol (51). Ketone 50 (150 mg, 0.45 
mmol) was treated with a solution of methyl lithium in ether (1 M, 2.0 mL) at laboratory 
temperature. After 2 h, the mixture was worked up as usual. Compound 51 was obtained as 
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white crystals (150 mg, 96%), mp 137-138 
o
C (acetone/heptane; ref.
68
 records 135-136 
o
C). 
[]D +26 (c 25.7). IR (CHC3): 3604, 1082 (OH); 1474, 1372, 1296, 1099, 948 (ketal). 
1
H 
NMR:  0.94 s (3H, H-18); 1.12 s (3H, H-19); 1.28 s (3H, H-21); 1.41 s (3H, H-11a); 1.98 d 
(1H, J=14.2); 2.12 dt (1H, J=12.6 and 3.4); 3.94 m (8H, W=76.3, ethylene dioxy groups). 
   3,3,20,20-Bis-ethylenedioxy-11α-methyl-5-pregnan-11-ol (52). Ketone 29 (450 mg, 
1.05 mmol) was treated with methyl lithium as above. The crude product (466 mg, 100%), not 
characterised, was immediately used to produce olefins 54 and. 55. 
   11-Methylene-5-pregnane-3,20-dione (53). 11-Alcohol 51 (450 mg, 1.1 mmol) was 
dissolved in formic acid (10 mL) and kept at rt for 20 h. The solution was concentrated on a 
rotary evaporator and the remainder was dissolved in toluene (20 mL) and washed with a 
solution of potassium hydrogencarbonate. Usual workup yielded white crystals of crude dione 
53 (220 mg, 63%). After three crystallisations, mp was 216-218 
o
C (toluene/heptane). []D 
+95 (c 0.2). IR (CHCl3):  3121, 1638, 1420, 907 (C=C); 1703, 597 (C=O). 
1
H NMR  0.56 
s (3H, H-18); 1.25 s (3H, H-19); 2.13 s (3H, H-21); 2.58 t (1H, J=8.97, H- 17α); 2.71 m (1H, 
W=22.8, H-12); 4.98 d (2H, J = 9.1, C=CH2). Anal. (C22H32O2) C, H. 
   11-Methyl-5-pregn-9(11)-ene-3,20-dione (55). Alcohol 52 (465 mg, 1.07 mmol) was 
dehydrated with formic acid as above. Flash chromatography of the product (silica gel, 
toluene, ethyl acetate, 9:1) yielded white crystals of the lipophilic component (55, 177 mg, 
49%), mp 141-143 
o
C (acetone/heptane). []D +119 (c 0.2). IR (CHCl3): 1703, 1418, 597 
(C=O); 1638 (C=C). 
1
H NMR: 0.56 s (3H, H-18); 1.45 s (3H, H-19); 1.85 bs (1H, W=2.6, 
H-11a); 2.15 s (3H, H-21); 2.57 t (1H, J=9.3, H-17α). Anal. (C22H32O2) C, H.   
   11-Methylene-5-pregnane-3,20-dione (54). The more polar fractions of the above 
chromatography yielded compound 54 as white crystals (90 mg, 25%), mp 138-139 
o
C 
(acetone/heptane). []D +104 (c 0.15). IR (CHCl3): 1703, 1358, 603 (C=O); 3116, 1639, 910 
(C=C). 
1
H NMR:  0.57 s (3H, H-18); 1.29 s (3H, H-19); 2.14 s (3H, H-21); 2.49 d (1H, 
 33 
J=11.6, H-9α); 2.60 t (1H, J=9.0, H-17α); 2.68 m (1H, W=24.4, H-12); 4.96 s (1H, H-11a); 
5.06 s (1H, H-11a’). Anal. (C22H32O2) C, H.  
   3α-Hydroxy-11-methyleno-5α-pregnan-20-one (56). Diketone 53 (150 mg, 0.46 mmol) 
was treated with hydrogen hexachloroiridate hydrate and 2-propanol as in the preparation of 
compound 15. PLC yielded the target compound 56 (90 mg, 65%) as white crystals, mp 153-
155 
o
C (acetone/heptane). []D +102.3 (CHCl3, c 0.3). IR (CHCl3): 3615, 3465, 3596, 1005, 
(OH); 3112, 1637, 1420, 904, 529 (C=C); 1699, 597 (C=O). 
1
H NMR:  0.54 s (3H, H-18); 
1.02 s (3H, H-19); 2.12 s (3H, H-21); 4.05 m (1H, W=15.2, H-3); 4.92 d (2H, J=10, H-11a). 
Anal. (C22H34O2) C, H. 
   3-Hydroxy-11-methylene-5-pregnan-20-one (57). In analogy with the preparation of 
compound 34, 3,20-diketone 54 (70 mg, 0.21 mmol) was reduced with sodium borohydride in 
pyridine to yield compound 57 (53 mg, 75%), mp 203-204 
o
C (acetone/heptane). []D +86.5 
(c 0.2). 
1
H NMR:  0.53 s (3H, H-18); 1.19 s (3H, H-19); 2.12 s (3H, H-21); 2.43 d (1H, 
J=11.9, H-12); 2.58 t (1H, J=9.0, H-17α); 3.68 m (1H, W=31.6, H-3); 4.90 s (1H, H-11a); 
5.00 s (1H, H-11a’). Anal. (C22H34O2) C, H.  
   3-Hydroxy-11-methyl-5-pregn-9(11)-en-20-one (58). Analogously, 3,20-Diketone 55 
(150 mg, 0.45 mmol) was selectively reduced to yield compound 58 (46 mg, 31%), mp 145-
147 
o
C (acetone/heptane). []D +56.4 (c 0.2). IR (CHCl3) 3609, 3455, 1037 (OH); 1698, 586, 
1359 (COCH3); 1389, 1379 (CH3). 
1
H NMR:  0.50 s (3H, H-18); 1.09 s (3H, H-19); 1.81 s 
(3H, H-11a); 2.14 s (3H, H-21); 2.58 t (1H, J=9.2, H-17α); 3.72 m (1H, W=36.2, H-3). Anal. 
(C22H34O2) C, H.
 
   3α-Hydroxy-11-methyl-5α-pregnan-20-one (59).  Olefin 56 (35 mg, 0.11 mmol) was 
hydrogenated in ethanol (5 mL) in the presence of palladium on charcoal (30 mg, 10%). 
Compound 59 (34 mg, 97%) forms white crystals, mp 193-195 
o
C (acetone/heptane). []D 
+142.8 (CHCl3, c 0.2). IR (CHCl3): 3616, 3468, 1002 (OH); 593 (C=O). 
1
H NMR:  0.69 s 
 34 
(3H, H-18); 0.88 s (3H, H-19); 1.08 d (3H, I=7.6, H-11a); 2.15 s (3H, H-21); 2.44 t (1H, 
J=9.0, H-17α); 4.04 m (1H, W=12.2, H-3). Anal. (C22H36O2) C, H. 
   3-Hydroxy-11-methyl-5-pregnan-20-one (60). Analogously, olefin 57 yielded 
compound 60 as white crystals (67%), mp 162-164 
o
C (acetone, heptane). []D +99 (c 0.2). IR 
(CHCl3): 3609, 3455, 1037 (OH); 1698, 586 (C=O). 
1
H NMR:  0.68 s (3H, H-18); 1.04 s 
(3H, H-19); 1.08 d (3H, d, J=7.8, H-11a); 2.12 s (3H, H-21); 2.45 t (1H, J=9.2, H-17α); 3.67 
m (1H, W=39.9, H-3). Anal. (C22H36O2) C, H. 
 
 
Biological Evaluation    
In vitro test using intact neurons in culture. Primary cultures of cortical neurons were 
obtained from cerebral cortices of 16-day-old mouse embryos.
43,44,69
 
The dissociated cells 
were suspended in Dulbecco’s Minimum Essential Medium supplemented with sodium 4-
aminobenzoate, insulin, penicillin, and 10% fetal calf serum, and seeded in 24-multiwell 
plates precoated with poly-L-lysine. Cultured cells were incubated for 7-9 days in a 
humidified 5% CO
2
/95% air atmosphere at 36.8 °C. To prevent glial proliferation, a mixture 
of 5 µM 5-fluoro-2’-deoxyuridine and 20 µM uridine was added into the culture 48 hr earlier.  
[
3
H]Flunitrazepam Binding. Benzodiazepine binding to intact cultured cortical neurons 
was determined as previously described
43,44,70
 
 
using 1.3–2.0 nM [3H]flunitrazepam. Prior to 
incubation with the radioligand, the plates were washed three times with 1 mL/well of HEPES 
buffer (136 mM NaCl, 5.4 mM KCl, 1.2 mM CaCl2, 1.4 mM MgCl2, 1.0 mM NaH2PO4, 10 
mM HEPES, and 9 mM glucose adjusted to pH 7.3) and the binding assay took place in the 
culture well in the presence of the HEPES buffer, [
3
H]flunitrazepam, and drug solutions. 
After 30 min incubation at 25 
o
C without shaking, a cold buffer was added, and rapidly 
removed by suction. The cells were rinsed three times with the cold buffer, then they were 
disaggregated in 0.2 N NaOH overnight, and their radioactivity was determined by liquid 
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scintillation counting (with cocktail Optiphase ‘Hisafe’2). Non-specific binding was 
determined in the presence of 20 µM diazepam. All the experiments were simultaneously run 
with a parallel experiment that determined the increase of the [
3
H]flunitrazepam binding 
induced by 100 µM GABA or 60 µM allopregnanolone, which were used as positive assay 
control. Solutions of tested compounds were prepared in dimethylsulfoxide (DMSO) and 
diluted in HEPES buffer to the assay concentrations (1 nM–300 µM). The final DMSO 
concentration in HEPES buffer was < 0.5%. Occasionally, 2% DMSO was used when the 
compounds were tested at concentrations > 100 μM. DMSO was also present in the HEPES 
control solutions.  
    Data analysis. Data shown represent the mean ± standard deviation (sd). Sigmoid curves 
were fitted to concentration-response data, and statistical analyses were performed using 
GraphPad Prism (GraphPad Software Inc, San Diego, CA, USA). At least six concentrations 
of tested compounds were used in the concentration-response curves, and each point was 
determined in triplicate.  
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    Supporting Information Available: Results of combustion analysis, full details of 3D-
QSAR analysis and computational methods are included. This material is available free of 
charge via the Internet at http://pubs.acs.org. 
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Tables, Figures, Schemes 
Table 1. Effect of the synthetic analogues synthesized in this work on [
3
H]flunitrazepam 
binding in primary cultures of cortical neurons  
 
# EC50 (µM) E100 μM  
3 4.6  1.6 92  11 
12 173  38 28  15 
13 7.4  3.5 67  27 
15 46  3 60  4 
19 > 100 0 
24 > 300 0 
28 71  30 43  19 
31 > 300 25  4 
32 75  55 61  22 
33 > 100 0 
34 94  25 42  12 
37 14  10 91  23 
38 1.2  0.7 116  20 
39 > 300 28  24 
44 32  7 117  9 
45 32.0  16.0 87  7 
47 154  78 45  19 
48 5.9  2.8 140  33 
49 > 300 9  12 
 48 
56 1.2  0.7 102  22 
57 37.5 ± 0.05 28  14 
58 3.0  1.9 97  16 
59 8  5 97  41 
60 14  12 71  23 
 
Values are mean ± sd (n = 2-4). The effect of 100 µM neurosteroid was related to the maximum effect on 
[
3H]flunitrazepam binding  obtained with 60 μM allopregnanolone. E100 μM of a  compound is expressed in % of  
Emax of allopregnanolone. 
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Table 2. Most relevant statistical parameters and correlation between experimental and 
calculated EC50 values (expressed as pEC50 =  –log EC50 in molar units) for the best CoMSIA 
model obtained for compounds 1a, 3, 12, 13, 15, 24, 39, 44, 45, 47 to 49, 56 and 59. 
 
a
 Number of principal components. 
b
 Average q
2
 from 10 runs of random groups 
cross validation (5 groups). 
c
 Average predictive error sum of squares from 10 
runs of random groups cross validation (5 groups). 
d
 Standard error of estimate. 
 CoMSIA-2 
 
PC 
a
 2 
q
2
 (CV) 
b
 0.60 ± 0.04 
PRESS (CV) 
c
 0.72 ± 0.03 
SEE 
d
 0.41 
r
2
 0.87 
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Figures 
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H
H H
H
COCH3
R2
3, alphaxolone, R1=OH, R2=O
4, R1=NH2, R
2=H2
R1
1a, allopregnanolone, R1= 5-H, R2=H
1b, pregnanolone, R1= 5-H, R2=H
2,   R1= 5-H, R2=OH, 3,5-tetrahydro-
      deoxycorticosterone  
Figure 1. Basic GABAA-receptor modulating steroids and some of their analogues 
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Figure 2. a: STDev
*
Coeff contour plots for CoMSIA-2 model overlaid on the structure of 
compound 1: Blue (B) and red (R) surfaces represent the electrostatically favoured (contour at 
75% contribution level) and disfavoured (contour at 25% contribution level) regions, i.e. 
regions where positive potential on the ligand atoms increase or decrease the activity of the 
compounds; a green (G) surface represents the hydrophobically favoured region (contour at 
80% contribution), where hydrophobic groups of the ligand increase the activity of the 
compound; b-d: Positive (blue surface, contour at 90% level) and negative (red surface, 
contour at 10% level) electrostatic fields and favoured hydrophobic field (green surface, 
contour at 90% level) contour maps of compounds 3 (b), 48 (c), and 24 (d).  
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Legends  
 
Ad Scheme 1 
 
a
 Reagents and Conditions: (a) MsCl, py; (b) TsCl, py; (c) KNO2, DMF, 130 
o
C; (d) BzCl, py; 
(e) NaBH4, EtOAc-MeOH; (f) Ac2O, AcOH, 180 
o
C; CrO3, AcOH-dichlorethane; AcOH, 
reflux; H2, Pd/C, toluene; (g) KOH, MeOH; (h) K2CO3, MeOH; MsCl, AcOEt; py, 180 
o
C; 
KOH, MeOH (i) LiAlH4, THF; CrO3, AcOH; (j) H2IrCl6·6H2O, H3PO3, 
i
PrOH-H2O, 90 
o
C; 
(k) NH2OH·HCl, py, 60 
o
C; (l) NaBH4, MoO3, MeOH; (m) K2CO3, MeOH. 
 
 
 
Ad Scheme 2 
 
a
 Reagents and Conditions: (a) Ac2O, AcOH, 180 
o
C; CrO3, AcOH-dichlorethane; AcOH, 
reflux; H2, Pd/C, EtOAc; (b) NH4OAc, NaCNBH3, 
t
BuOH; (t-BuO)2CO, py; CrO3, MeCOMe; 
(c) K2CO3, MeOH; (d) MsCl, py; NaNO2, HMPA, 90 
o
C; (e) TFA, acetone. 
 
 
 
Ad Scheme 3 
 
a
 Reagents and Conditions: (a) H2, Pd/C, py; (b) NaBH4, py; (c) CrO3, MeCOMe; ethylene 
glycol, p-TsOH; (d) CrO3, MeCOMe; ethylene glycol, p-TsOH; (e) LiAlH4, THF; (f) AcOH, 
MeOH, H2O, 60 
o
C; (g) HCCMgBr or C6H5CCMgBr, THF. 
 
 
 
Ad Scheme 4 
 
a
 Reagents and Conditions: (a) H2IrCl6·6H2O, 
i
PrOH; (b) H2, Pd/C, EtOH-AcOEt; K2CO3, 
MeOH-H2O, reflux; (c) MsCl, py; (d) KNO2, DMF, 130 
o
C; (e) ethylene glycol, p-TsOH; (f) 
LiAlH4 or HCCMgBr, THF; (g) AcOH, MeOH, H2O, 60 
o
C; (h) NH2OH·HCl, KOH, EtOH, 
86 
o
C; (i) Na, 
i
PrOH; HCl aq., THF; (j) MoO3, NaBH4, MeOH; HCl aq., THF. (k) mCPBA, 
CHCl3. 
 
 
 
Ad Scheme 5 
 
a
 Reagents and Conditions: (a) MeLi, Et2O; (b) HCOOH, 20 
o
C; (c) H2IrCl6·6H2O, H3PO3, 
i
PrOH; (d) H2, Pd/C, EtOH; (e) NaBH4, py. 
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Table  S1. Results of combustion analyses of newly prepared compounds* 
 
 
 
*Combustion analyses were carried out using Perkin Elmer 2400 in the Analytical Laboratory 
of the Institute of Organic Chemistry and Biochemistry, Dr. S. Matějková, Head. 
Subst. Formula Calculated Found 
6 C28H44O6S 66.11 %C, 8.72 %H,  6.30 %S 59.88 %C, 8.76 %H,  6.03 %S 
7 C34H48O6S 69.83 %C, 8.27 %H,  5.48 %S 69.59 %C, 8.35 %H,  5.73 %S 
8 C27H42O4 75.31 %C, 9.83 %H 75.29 %C, 9.86 %H 
9 C34H46O5 76.37 %C, 8.67 %H 76.21 %C, 8.53 %H 
10 C34H48O5 76.08 %C, 9.01 %H 76.13 %C, 9.11 %H 
11 C30H40O5 74.97 %C, 8.39 %H 75.18 %C, 8.28 %H 
12 C21H34O3 75.41 %C, 10.25 %H 75.28 %C, 10.21 %H 
13 C21H30O2 79.70 %C, 10.19 %H 79.52 %C, 10.26 %H 
15 C21H34O3 75.41 %C, 10.25 %H 75.36 %C, 10.28 %H 
16 C27H43NO4 72.77 %C, 9.73 %H, 3.14 %N 72.50 %C, 9.64 %H, 3.15 %N 
17 C27H45NO3 75.13 %C, 10.51 %H, 3.24 %N 74.90 %C, 10.61 %H, 3.53 %N 
18 C27H45NO3 75.13 %C, 10.51 %H, 3.24 %N 74.95 %C, 10.55 %H, 3.49 %N 
19 C23H37NO3 73.56 %C, 9.93 % H, 3.73 % N 73.49 %C,  9.98 % H, 3.85 % N 
21 C28H45NO5 70.70 %C,  9.54 %H, 2.94 %N 70.49 %C,  9.64 %H, 3.05 %N 
22 C26H43NO4 72.02 %C, 10.00 %H, 3.23 %N 71.78 %C, 10.08 %H, 3.32 %N 
23 C26H43NO4 72.02 %C, 10.00 %H, 3.23 %N 72.07 %C, 10.19 %H, 3.42 %N 
24 C21H35NO2 75.63 %C, 10.58 %H, 4.20 %N 75.54 %C, 10.47 %H, 4.42 %N 
32 C25H34O3 78.49 %C, 8.96 %H 78.31 %C, 9.01 %H 
33 C37H42O3 83.11 %C, 7.92 %H 83.19 %C, 8.04 %H 
35 C23H32O3 77.49 %C, 9.05 % H 77.34 %C, 9.11 % H 
36 C29H36O3 80.52 %C, 8.39 %H 80.48 %C, 8.46 %H 
37 C23H34O3 77.05 %C, 9.56 %H 77.16 %C, 9.75 %H 
38 C29H38O3 80.14 %C, 8.81 %H 79.95 %C, 8.86 %H 
42 C22H34O5S 64.36 %C, 8.35 %H, 7.81 %S 64.18 %C, 8.52 %H, 7.55 %S 
45 C23H34O3 77.05 %C, 9.56 %H 76.79 %C, 9.72 %H 
47 C21H35NO2 75.63 %C, 10.58 %H, 4.20 %N 75.42 %C, 10.39 %H, 4.27 %N 
48 C21H35NO2.H2O 73.64 %C, 10.59 %H, 4.09 %N 73.25 %C, 10.77 %H, 4.22 %N 
49 C21H32O3 75.86 %C, 9.70 %H 75.85 %C, 9.67 %H 
50 C25H38O5 71.74 %C, 9.15 %H 71.49 %C, 9.26 %H 
53 C22H32O2 80.44 %C, 9.82 %H 80.39 %C, 9.85 %H 
54 C22H32O2 80.44 %C, 9.82 %H 80.48 %C, 9.91 %H 
55 C22H32O2 80.44 %C, 9.82 %H 80.21 %C, 9.79 %H 
56 C22H34O2 79.95 %C,10.37 %H 79.68 %C,10.19 %H 
57 C22H34O2 79.95 %C,10.37 %H 79.79 %C,10.44 %H 
58 C22H34O2 79.95 %C,10.37 %H 79.98 %C,10.52 %H 
59 C22H36O2 79.46 %C, 10.91 %H 79.19 %C, 11.20 %H 
60 C22H36O2 79.46 %C, 10.91 %H 79.29 %C, 10.96 %H 
 3
 Selection of 3D-QSAR methodology and compounds  
 
The CoMFA and CoMSIA methodologies1 were explored in order to obtain 3D-QSAR 
models that would correlate the experimental flunitrazepam binding activity with the 
structural properties of the compounds. Both methods assume that the compounds interact 
with the receptor at the same place and with similar relative geometry. Briefly, they start from 
a set of prealigned conformations, which ideally reflect the “active“ conformation of each 
compound, and imply the following steps: (1) a cubic grid is defined around the molecules, 
(2) different atomic probes are used to calculate field values at each grid point, (3) the 
resulting table of values, normally constituted by thousands of columns, is analysed using the 
Partial Least Squares regression method (PLS) to correlate biological activities using an 
optimum number of latent variables (or principal components, PC), (4) the model is validated 
by determining the internal predictivity (crossvalidation) and, if possible, by predicting the 
biological activity of an external set of molecules. CoMFA and CoMSIA methods differ 
mainly on the types of fields considered and their potential functional forms. Thus, CoMFA 
normally relies on the calculation of steric and electrostatic fields derived from Lenard-Jones 
and Coulomb interaction potentials, while CoMSIA is based on the calculation of steric, 
electrostatic, hydrophobic, donor and acceptor similarity indexes. 
Concerning the compounds, in the present work two series have been synthesised, namely a 
5α- and a 5β-collection, which can be considered analogues of the parent neurosteroids 
allopregnanolone (1a) and pregnanolone (1b) (Tables S1 and S2). Given the small number of 
compounds on each series (15 and 11, respectively) the separation of a test set to carry out an 
external validation was discarded from the beginning. However, it was assumed that models 
supported by a strong enough internal validation (ie. q2 ≥ 0.6) could provide some information 
about the main structural features that determine the activity of the compounds considered. To 
that end, both the CoMFA and CoMSIA methods were attempted for the generation of 3D-
QSAR models from the whole set of 5α- and 5β-compounds as well as from each series 
separately. 
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Table S2. Structures of 5α-steroids with their activities expressed as pEC50 (ie. -log EC50 (M)), logP and logS (log solubility in water (M)) molecular 
descriptors calculated by different methods,a and calculated squared correlation coefficient (r2) of activity vs. each descriptor. 
 
 
 pEC50 cLogP VG KLOP PHYS ALOGPs AC_logP ALOGP MLOGP KOWWIN XLOGP2 XLOGP3 miLogP
Mean
±SD ALOGpS AClogS Mean 
1a 
 
6.06 b 4.51 4.22 3.80 3.94 4.28 3.71 3.73 4.25 3.97 4.83 4.86 4.18 4.19 ±0.39 -5.37 -4.76 -5.07 
56 5.92 4.55 4.15 3.63 4.00 3.60 3.93 3.79 4.36 4.39 4.42 4.30 4.49 4.13 ±0.34 -5.46 -4.82 -5.14 
3 5.34 3.73 3.60 2.85 2.74 3.23 3.04 2.38 3.31 2.63 3.60 3.24 3.07 3.12 ±0.42 -4.14 -4.41 -4.28 
48 5.23 2.52 2.88 2.35 2.48 2.71 2.34 2.28 3.42 2.43 3.95 3.26 2.77 2.78 ±0.52 -4.07 -4.43 -4.25 
13 
 
5.13 4.03 3.96 3.35 3.57 3.96 3.61 3.29 4.15 3.76 4.11 4.38 3.67 3.82 ±0.33 -5.12 -4.53 -4.83 
59 5.10 5.03 4.55 4.07 4.21 4.28 3.90 3.99 4.47 4.39 5.34 5.12 4.65 4.50 ±0.46 -5.54 -4.91 -5.23 
44 4.49 3.58 2.93 2.40 2.70 3.00 2.87 2.57 3.42 2.84 4.01 3.52 3.26 3.09 ±0.47 -3.84 -4.36 -4.10 
45 4.49 4.17 2.94 2.72 2.83 2.93 2.67 3.61 3.74 3.02 4.03 3.42 3.49 3.30 ±0.52 -4.71 -4.79 -4.75 
15 
OH
 
4.34 3.12 3.00 2.49 2.78 3.23 2.87 2.63 3.42 2.84 4.01 3.52 3.26 3.10 ±0.42 -3.89 -4.36 -4.13 
 5 
47 3.81 2.52 2.88 2.35 2.48 2.71 2.34 2.28 3.42 2.43 3.95 3.26 2.77 2.78 ±0.52 -4.07 -4.43 -4.25 
12 
OH
 
3.76 3.12 3.00 2.49 2.78 3.23 2.87 2.63 3.42 2.84 4.01 3.52 3.26 3.10 ±0.42 -3.89 -4.36 -4.13 
19 <4.2 c 3.02 2.78 2.09 2.53 3.26 2.89 2.37 3.34 2.37 4.22 3.52 3.04 2.95 ±0.59 -4.69 -4.63 -4.66 
24 
 
<3.5 c 3.20 2.95 2.44 2.55 3.07 2.34 2.34 3.42 2.43 3.95 3.26 2.77 2.89 ±0.51 -4.12 -4.43 -4.28 
39 <3.5 c 3.58 2.93 2.40 2.70 3.00 2.87 2.57 3.42 2.84 4.01 3.52 3.26 3.09 ±0.47 -3.84 -4.36 -4.10 
49 
 
<3.5 c 2.86 3.15 2.79 2.82 2.71 2.51 2.50 3.42 2.46 3.58 3.54 3.45 2.98 ±0.43 -4.23 -4.44 -4.34 
 r2 d  0.37 0.54 0.51 0.45 0.35 0.45 0.29 0.40 0.40 0.17 0.34 0.35 0.42 0.49 0.31 0.46 
a logP calculations: clogP calculated with Sybyl 8.0 (Tripos International); VG, KLOP and PHYS logP values calculated with Marvin 5.11.4 
(2012, ChemAxon, http://www.chemaxon.com); ALOGPs, AC_logP, ALOGP, MLOGP, KOWWIN, XLOGP2 and XLOGP3 calculated on-line 
with the ALOGPS 2.1 web applet2 (http:// http://www.vcclab.org/lab/alogps/); miLogP calculated on-line with the Molinspiration Property 
Calculation Service (http://www.molinspiration.com). logS calculations: ALOGpS and AClogS calculated on-line with the ALOGPS 2.1 web 
applet2 (http:// http://www.vcclab.org/lab/alogps/). b From reference [3b]. c Only a low limit for the EC50 could be experimentally determined. d 
Calculated from compounds with a defined pEC50 value (ie. 1a, 56, 3, 48, 13, 59, 44, 45, 15, 47 and 12). 
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Table S3. Structures of 5β-steroids with their activities expressed as pEC50 (ie. -log EC50 (M)), logP and logS (log water solubility (M)) molecular 
descriptors calculated by different methods,a and calculated squared correlation coefficient (r2) of activity vs. each descriptor. 
 
 
 pEC50 cLogP VG KLOP PHYS ALOGPs AC_logP ALOGP MLOGP KOWWIN XLOGP2 XLOGP3 miLogP
Mean
±SD ALOGpS AClogS Mean 
1b 
 
5.93 b 4.51 4.22 3.80 3.94 4.28 3.71 3.73 4.25 3.97 4.83 4.86 4.18 4.19 ±0.39 -5.37 -4.76 -5.07 
38 5.92 5.29 4.74 4.81 4.84 4.80 5.14 4.60 4.69 4.78 6.14 5.20 5.15 5.02 ±0.42 -5.76 -6.39 -6.08 
58 5.52 4.55 3.93 3.44 4.10 4.46 4.20 3.93 4.36 4.44 3.62 3.85 4.54 4.12 ±0.37 -4.34 -4.61 -4.48 
37 4.85 4.17 2.94 2.72 2.83 2.93 2.67 3.61 3.74 3.02 4.03 3.42 3.49 3.30 ±0.52 -4.71 -4.79 -4.75 
60 4.85 5.03 4.55 4.07 4.21 4.28 3.90 3.99 4.47 4.39 5.34 5.12 4.65 4.50 ±0.46 -5.54 -4.91 -5.23 
57 4.43 4.55 4.15 3.63 4.00 3.60 3.93 3.79 4.36 4.39 4.42 4.30 4.49 4.13 ±0.34 -5.46 -4.82 -5.14 
28 4.15 3.58 2.93 2.40 2.70 3.00 2.87 2.57 3.42 2.84 4.01 3.52 3.26 3.09 ±0.47 -3.84 -4.36 -4.10 
 7 
32 
 
4.12 4.76 2.95 3.05 2.95 2.90 2.47 4.66 4.07 3.19 4.05 3.33 3.72 3.51 ±0.74 -4.66 -5.22 -4.94 
34 4.03 3.73 3.60 2.85 2.74 3.23 3.04 2.38 3.31 2.63 3.60 3.24 3.07 3.12 ±0.42 -4.14 -4.41 -4.28 
33 
 
<4.0 c 7.00 6.56 7.23 6.98 5.71 7.41 6.63 5.85 6.72 8.26 6.88 7.05 6.86 ±0.67 -5.66 -8.43 -7.05 
31 <3.5 c 3.58 2.93 2.40 2.70 3.00 2.87 2.57 3.42 2.84 4.01 3.52 3.26 3.09 ±0.47 -3.84 -4.36 -4.10 
 r2 d  0.33 0.42 0.51 0.58 0.71 0.54 0.23 0.47 0.50 0.33 0.50 0.50 0.56 0.32 0.24 0.34 
a logP calculations: clogP calculated with Sybyl 8.0 (Tripos International); VG, KLOP and PHYS logP values calculated with Marvin 5.11.4 
(2012, ChemAxon, http://www.chemaxon.com); ALOGPs, AC_logP, ALOGP, MLOGP, KOWWIN, XLOGP2 and XLOGP3 calculated on-line 
with the ALOGPS 2.1 web applet2 (http:// http://www.vcclab.org/lab/alogps/); miLogP calculated on-line with the Molinspiration Property 
Calculation Service (http://www.molinspiration.com). logS calculations: ALOGpS and AClogS calculated on-line with the ALOGPS 2.1 web 
applet2 (http:// http://www.vcclab.org/lab/alogps/). b From reference [3b]. c Only a low limit for the EC50 could be experimentally determined. d 
Calculated from compounds with a defined pEC50 value (ie. 1b, 38, 58, 37, 60, 57, 28, 32 and 34). 
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3D-QSAR analysis  
   The structures of the 5- and 5-steroids were respectively aligned to the lowest energy 
conformations of allopregnanolone and pregnanolone (Figures S1 and S2), previously 
determined by conformational analysis, and the best global alignment of the two series was 
also determined. 
Figure S1. Alignments of the 5- and 5-neurosteroid analogs (left and right, respectively). 
 
   Attempts to obtain a CoMFA or CoMSIA model using the global alignment of all the 
compounds were unsuccessful (i.e. statistical parameters showed low significance, results not 
shown), as expected considering the hypothesis that 5- and 5-neurosteroids could have 
different binding-sites at the GABAA receptor.3 Poor results were also obtained when using 
only the compounds from the 5-series or the CoMFA fields for compounds of the 5-series 
(results not shown). However, good COMSIA models (Table S2) were obtained when using 
the electrostatic and hydrophobic fields of the compounds from the 5-series 1a, 3, 12, 13, 
15, 24, 39, 44, 45, 47, 48, 49, 56, and 59. 
   Hence, CoMSIA models -1 and -2 showed statistically significant leave-one-out q2 values of 
0.61 (1 Principal Component, PC) and 0.67 (2 PC), respectively. Further crossvalidation with 
5 random groups yielded q2 values of 0.57 and 0.60, while non-crossvalidated PLS resulted 
on r2 values of 0.82 and 0.87, respectively, indicating a good correlation between the 
observed and calculated EC50 values, particularly for model CoMSIA-2 (Figure S2). Taking 
also into account the steric and/or donor fields did not result in any improvement of the 
models, while considering the acceptor field resulted on similar or slightly improved models 
(CoMSIA-3, -4 and -5, see Table S2). However, analysis of the acceptor field contribution 
indicated that this improvement was most likely derived from overfitting the data. 
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Table S4. Statistical parameters of the different CoMSIA models built from the alignment of 
compounds 1a, 3, 12, 13, 15, 24, 39, 44, 45, 47, 48, 49, 56 and 59. 
 
 CoMSIA-1 CoMSIA-2 CoMSIA-3 CoMSIA-4 CoMSIA-5 
q2 (LOO) a 0.61 0.65 0.60 0.69 0.72 
PRESS (LOO) b 0.68 0.67 0.69 0.64 0.64 
PC c 1 2 1 2 3 
q2 (CV) d 0.57 ± 0.07 0.60 ± 0.04 0.52 ± 0.12 0.63 ± 0.05 0.70 ± 0.07 
PRESS (CV) e 0.71 ± 0.06 0.72 ± 0.03 0.75 ± 0.09 0.69 ± 0.05 0.65 ± 0.08 
SEE f 0.47 0.41 0.39 0.32 0.29 
r2 0.82 0.87 0.87 0.92 0.94 
F-value 53.6 36.5 79.8 63.4 53.6 
Fraction: 
    Hydrophobic 
    Electrostatic 
    Acceptor 
 
0.35 
0.65 
 
0.40 
0.60 
 
0.25 
0.45 
0.30 
 
0.27 
0.42 
0.31 
 
0.27 
0.42 
0.31 
a Leave-one-out q2. b Leave-one-out predictive error sum of squares. c Number of 
principal components. d Average q2 from 10 runs of random groups cross validation (5 
groups). e Average predictive error sum of squares from 10 runs of random groups cross 
validation (5 groups). f Standard error of estimate. 
 
 
 
 
Figure S2. Correlations between experimental and calculated EC50 values (expressed as 
pEC50 =  –log EC50 in molar units) for the best CoMSIA models. 
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Computational Methods  
Molecular modelling and structural alignment. Compounds were built in their neutral state 
(i.e. unprotonated amine groups for compounds 24, 47 and 48) and energy minimized using 
the program suite MOE.4 The implemented MMFF94s force field5 was used for all energy 
calculations. Conformational searches were carried out using the LowModeMD method6 
implemented in the same program with its default parameters. Compounds were structurally 
aligned using the lowest energy conformations of allopregnanolone and pregnanolone as 
templates for the 5α- and 5β-series, respectively, and the Flexible Alignment application 
implemented in MOE. This alignment algorithm flexibly aligns molecules by maximizing 
steric and feature overlap while minimizing internal ligand strain.7 Each alignment is given a 
score that quantifies the quality of the alignment as the sum of the average strain energy of the 
molecules (calculated as the sum of the individual forcefield potential energies divided by the 
number of molecules) plus a similarity measure of the alignment (calculated as a P-density 
overlap function that scores the degree of feature overlap among compounds). Thus, 
parameters were adjusted to achieve the best superposition of the steroid skeleton, as well as 
the hydrogen bond donor and acceptor groups. The best scored alignments were then refined 
with the same algorithm but this time allowing the free movement of all the compounds, 
including the templates. 
Dataset for 3D-QSAR. The compounds from the 5-series 1a, 3, 12, 13, 15, 24, 39, 44, 45, 
47, 48, 49, 56 and 59 were chosen as training-set to develop the 3D-QSAR models. 
Compound 19 was excluded from this study since it was only tested at concentrations up to 
100 μM and its EC50 could not be determined. Compounds 24, 39 and 49 were arbitrarily 
assigned an EC50 value of 1 mM (other values were tried up to 10 mM that yielded similar 
results) based on the experimentally determined low limit (>300 μM) for their real EC50. 
Given the relatively small number of compounds, a test-set to carry out an external validation 
of the models could not be selected and only an internal validation of the models was carried 
out (see below). 
3D-QSAR methodology.  
Generation of CoMFA and CoMSIA fields. The program Sybyl8 and the aligned compounds 
with MMFF94s partial charges were used for the 3D-QSAR analysis. Potential fields for 
CoMFA (steric and electrostatic) and CoMSIA (steric, electrostatic, hydrophobic, donor and 
acceptor) were calculated using the default Sybyl settings. Thus, a 3D-cubic grid with 1 Å 
grid spacing, enclosing the aligned compounds and extending 4 Å beyond any of their atoms, 
was defined. The steric and electrostatic CoMFA fields were calculated from the Lennard-
Jones and coulombic terms of the interaction potential with the default sp3 charged C+ atom 
probe. The CoMSIA fields were derived according to Klebe et al.1b using the default probe 
with charge +1, radius 1 Å, hydrophobicity +1 and H-bond donor and acceptor property +1. 
PLS-based CoMFA and CoMSIA model derivation. Model derivation employing partial 
least-squares (PLS) regression was carried out as implemented in Sybyl. Leave-one-out 
(LOO) cross-validation, as determined by the SAMPLS method,9 was used for the fast 
determination of statistical significance (i.e. q2 and standard error of prediction, PRESS) of 
different combination of fields and parameters. Random groups cross validation using 5 
groups was repeated 10 times and average statistical values were calculated to further assess 
the robustness and statistical confidence of the best models. The final non cross-validated 
models were developed using the optimal number of components that had both the highest q2 
and smallest PRESS values. Quality of these models was assessed through calculation of their 
statistical parameters (i.e. squared correlation coefficient (r2), standard error of estimate (SEE) 
and F-value). 
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